

Rev No: 01 Version no. 02 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

Pharmacy Board of Sierra Leone PMB 322 Central Medical Stores Compound

New England Ville

Freetown





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

Table of contents

Acknowledgements	7
Executive summary	7
1. Introduction (background)	9
1.1. Objective	
2. Scope	O
3. Legal basis1	1
4. Guidance for implementation 1:	1
4.1. Reporting types	1
4.1.1. Notifications	2
4.1.2. Annual notification (AN)	3
4.1.3. Immediate notification (IN)	3
4.1.4. Minor variation (Vmin)	3
4.1.5. Major variation (Vmaj)	4
4.1.6. New applications and extension applications	4
4.1.7. Labelling information	4
4.2. Conditions to be fulfilled	5
4.3. Application and documentation required	5
5. Administrative changes and changes to a CEP or to a	
confirmation of API-prequalification document1	7
5.1. Change in the name and/ or corporate address of the MAH of the	
FPP	7
5.2. Change in the name or address of a manufacturer of an API 18	3
5.3. Change in the name and/or address of a manufacturer of the FPP \dots 18	3
5.4. Deletion of a manufacturing site or manufacturer	9





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Effective date: 17 May 2024 Issue date: 15 May Approved by: Registrar

2024

5.5. Submission of a new or updated CEP for an API or starting material	
or intermediate used in the manufacturing process of the API	
5.6. Submission of a new or updated confirmation of API-prequalification	23
5.7. Submission of a new or updated transmissible spongiform encephalopathy (TSE) CEP for an excipient or API (addition or	
replacement)	25
6. Quality Changes	26
6.1. Active Pharmaceutical Ingredient	26
3.2.S API (or Drug Substance)	26
3.2.S.2 Manufacture	
6.1.1. Replacement or addition of a new manufacturing site or	
manufacturer of an API	
6.1.2. Change or addition of a manufacturing block or unit at a currently	
accepted site of API manufacture	
6.1.3. Change in the manufacturing process of the API	34
6.1.4. Change in the in-process tests or limits applied during the	
manufacture of the API	
6.1.5. Change in batch size of the API or intermediate involving	41
6.1.6. Change or addition of a manufacturing block or unit at a currently	
accepted site of API manufacture	
3.2. S.4 Control of the API by the API manufacturer	46
6.1.7. Changes to the test parameters, acceptance criteria, or analytical	
procedures of the API manufacturer that do not require a change to the	
FPP manufacturer's API specifications involving	46
3.2. S.4 Control of the API by the FPP manufacturer	48
6.1.8. Change to the test parameters or acceptance criteria of the API	
specifications of the FPP manufacturer	48






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Effective date: 17 May 2024 Approved by: Issue date: 15 May Registrar

2024

6.1.9. Change to the analytical procedures used to control the API by the	
FPP manufacturer	
3.2.S.6 Container Closure System	
6.1.10. Change or addition of a manufacturing block or unit at a currently accepted site of API manufacture	
6.1.11. Change in the specifications of the immediate packaging for the	
storage and shipment of the API	
6.1.12. Change to an analytical procedure on the immediate packaging of the API	
6.1.13. Change in the retest period or shelf-life of the API involving	
6.1.14. Change in the labelled storage conditions of the API involving	
6.2. Finished Pharmaceutical Product (FPP) or drug product	
3.2. P.1 Description and composition of the FPP	
6.2.1. Change in the colouring system or the flavouring system currently	
used in the FPP involving	
6.2.2. Change in weight of tablet coatings or capsule shells involving	73
6.2.3. Change in the composition of an immediate-release solid oral	
dosage form	
6.2.4. Change or addition of imprints, embossing or other markings,	
including replacement or addition of inks used for product markings and	
change in scoring configuration	78
6.2.5. Changes in dimensions without change in qualitative or quantitative	
composition and mean mass of	80
3.2.P.3 Manufacture	82
6.2.6. Addition or replacement of a manufacturing site for part or all of	
the manufacturing process for an FPP involving:	82
$\textbf{6.2.7. Replacement or addition of a site involving batch control testing} \dots$	86
6.2.8. Change in the batch size of the FPP	87






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

6.2.9. Change in the manufacturing process of the FPP 90 6.2.10. Change to in-process tests or limits applied during the 6.2.11. Change in source of an excipient from a TSE risk to a material of 6.2.12. Change in the specifications or analytical procedures for an 6.2.13. Change in specifications of an excipient to comply with an 6.2.14. Change in the standard claimed for the FPP from an in-house to 6.2.15. Change in the specifications of the FPP involving test parameters and acceptance criteria100 6.2.17. Replacement or addition of a primary packaging type106 6.2.18. Change in the package size107 6.2.19. Change in the shape or dimensions of the container or closure.....109 6.2.20. Change in qualitative and/or quantitative composition of the immediate packaging material......110 6.2.21. Change in the specifications of the immediate packaging.............112 6.2.22. Change to an analytical procedure on the immediate packaging ...113 6.2.23. Change in any part of the (primary) packaging material not in contact with the FPP formulation (e.g., colour of flip-off caps, colour code rings on ampoules, or change of needle shield)115





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Effective date: 17 May 2024 Issue date: 15 May Approved by: Registrar

2024

integral part of the primary packaging (excluding spacer devices for
metered dose inhalers116
3.2.P.8 Stability
6.2.25. Change in the shelf-life of the FPP (as packaged for sale)117
6.2.26. Change in the in-use period of the FPP (after first opening or after reconstitution or dilution)
6.2.27. Change in the labelled storage conditions of the FPP (as packaged for sale), the product during the in- use period or the product after reconstitution or dilution
7. Safety and Efficacy Changes 122
7.1. Change(s) in the Summary of Product Characteristics, Labelling or Patient information leaflet of a generic/hybrid medicinal products following assessment of the same change for the reference product
7.2. Change(s) in the Summary of Product Characteristics, Labelling or Patient Information Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the <nmra></nmra>
7.3. Change(s) in the Summary of Product Characteristics, Labelling or Patient Information Leaflet due to new quality, non-clinical, clinical or pharmacovigilance data
7.4. Change in the legal status of a medicinal product126
7.5. Change(s) to therapeutic indication(s)127
7.6. Deletion of pharmaceutical form and a strength127
7.7. Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan
7.8. Other variations not specifically covered elsewhere in this guideline which involve the submission of studies to the <nmra></nmra>





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

8. Changes to the labelling or the patient information leaflet which are not connected with the summary of product characteristics 132
Definitions
References
Appendix 1: Examples of changes that make a new application or extension application necessary132
Appendix 2: Changes to excipients

Acknowledgements

The Pharmacy Board greatly appreciate the collaborative work of the Technical Working Group (TWG) consisting of representatives from the Food and Drugs Authority Ghana, Medicines Control Agency of The Gambia, Liberia Medicines and Health Products Regulatory Authority, The Pharmacy Board of Sierra Leone and The GHPP-PharmTrain Project team of the Federal Institute for Drugs and Medical Devices (BfArM, Germany) for preparing a Guideline on Variation, for adoption by the Pharmacy Board of Sierra Leone.

Executive summary

The variation guidelines help the reader to classify changes that may occur related to all the major sections of a dossier, to understand the considerations necessary to assess the risk of each change, and to determine the documentation required to support the change.

The change categories for the quality aspects are organized according to the structure of the common technical document (CTD). The specific CTD sections associated with individual data requirements have been identified





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


in order to assist in the filing of documentation (reproduced with corresponding numbers in bold). Changes are classified as major only in those instances where the level of risk is considered to be high and it is deemed necessary to provide the Pharmacy Board with adequate time for an assessment of the supporting documentation. Particular circumstances are identified where lower reporting requirements (annual notification (AN), immediate notification (IN) or minor variation (Vmin)) are possible. In all cases where notification to the Pharmacy Board or acceptance by the Board is required to implementation, assessment timelines will be published in order to provide predictable and reasonable timeframes.

In addition, the guidelines assist in understanding the possible consequences of the listed changes, and may be useful as a risk management tool to promote or enhance best practices within organizations.

This guideline has been developed by the Joint Technical Working Group for Guidelines in Marketing Authorization (TWG-MAG). The TWG-MAG consists of two representatives each of the national medicines regulatory authorities (NMRA) of Liberia (LMHRA, Liberia Medicines and Health Products Regulatory Authority), Sierra Leone (PBSL, Pharmacy Board of Sierra Leone), The Gambia (MCA, Medicines Control Agency), and Ghana (FDA, Food and Drugs Authority) and is facilitated by the GHPP PharmTrain2 Project team of the Federal Institute for Drugs and Medical Devices (BfArM, Germany).

This document should be read in conjunction with other applicable guidelines, such as Guidelines on the registration of Medicinal Products.





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar 2024

1. Introduction (background)

This guidance document is technically and structurally inspired by the European Union Institutions and Bodies Commission's Guideline on the details of the various categories of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products. It is intended to provide supportive information on how to present an application to implement a change to a product.

A Marketing Authorization Holder (MAH) is responsible for the safety, efficacy and quality of a product throughout its life-cycle. Therefore, the MAH is required to make changes to the details of the product in order to accommodate technical and scientific progress, or to improve or introduce additional safeguards for the authorized product. Such changes, whether administrative or substantive, are referred to as variations and may be subject to acceptance by PBSL prior to implementation.

Technical requirements for the different types of variations are set out in this guideline in order to facilitate the submission of appropriate documentation by MAHs and their assessment by the Pharmacy Board and to ensure that variations to the medicinal product do not result in health concerns.

The procedure for submitting variations is not within the scope of this guideline. MAHs are advised to consult information on the Board's web site whenever they are considering the submission of a variation application.

1.1. Objective

These guidelines are intended to assist marketing authorization holders with the classification of changes made to the quality, safety and efficacy parts of a finished pharmaceutical product (FPP) and also to provide guidance on the technical and other general data requirements to support





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

changes to the quality attributes of the active pharmaceutical ingredient (API) or FPP as well as the safety and efficacy of the FPP.

2.0 Scope


This guideline applies to MAHs intending to make changes to the quality, safety and efficacy sections of product dossiers for an active pharmaceutical ingredient (API) or a finished pharmaceutical product (FPP) for human use.

This guidance document is applicable only to APIs and excipients manufactured by chemical synthesis or semi-synthetic processes and FPPs containing such APIs and excipients. APIs produced by fermentation and APIs of biological, biotechnological or herbal origin is treated as special cases.

The notification requirements for API-related changes differ depending on the manner in which information on the API was submitted in the FPP application, namely, use of a WHO-prequalified API, use of a European Pharmacopoeia Certificate of Suitability (CEP), use of the API master file (APIMF) procedure, or as provided in full within the dossier, in line with the Pharmacy Board's registration guidelines.

The conditions and documentation stipulated in this guidance for API-related variations focus primarily on those FPPs that relied upon the provision of full API information within the FPP dossier. In general, FPPs that rely upon the APIMF procedure have reduced reporting requirements because the API manufacturers themselves have notified the relevant API-related change directly to the Board. Similarly, when an FPP relies upon Certificate of Suitability (CEP) or a prequalified API, FPP MAHs are required to notify the Board only when the associated CEP or Confirmation of API Prequalification document has been revised.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

Guidance for API manufacturers on the technical and procedural requirements for changes to prequalified APIs and to APIs supported by the APIMF procedure is available on the WHO-Prequalification programme's web site. Regardless of whether the API-related change is notified primarily by the API manufacturer (API prequalification (API-PQ) procedure, APIMF procedure or CEP), or the FPP manufacturer (full API information in dossier) the technical requirements are in principle the same as those stipulated in these WHO guidelines.

2. Legal basis


This guideline has to be read in conjunction with of Part IX Section 55 of the Pharmacy and Drugs Act, 2001. This guideline is coherent with national/regional frameworks and policies. The usage of the variation guideline by PBSL is supported/embedded in the relevant regulation, if applicable.

3. Guidance for implementation

3.1. Reporting types

The definitions outlined in the following reporting types are intended to provide guidance with respect to the classification of quality, efficacy and safety related changes. Specific examples of changes are provided in this guideline. However, it should be noted that a change not covered by this guideline, should be considered as a major change by default. Whenever the MAH is unclear about the classification of a particular change, the Pharmacy Board should be contacted. It remains the responsibility of the MAH to submit relevant documentation to justify that the change will not have a negative impact on the quality, safety and efficacy of the product.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

Individual changes normally require the submission of separate variations.

Grouping of variations is acceptable only under the following circumstances:


- 1. When variations are consequential to each other, e.g. introduction of a new impurity specification that requires a new analytical procedure;
- 2. When the same change affects multiple FPPs, e.g. addition of a new API manufacturing site for multiple FPPs;
- 3. When all the changes are annual notifications.

For the purposes of classification, an application involving two or more types of variations will be considered as the highest risk type, e.g. a variation grouping both a minor change and a major change will be classified as a major change.

MAHs are also advised to exercise caution whenever several changes to the same FPP are envisaged. Although each of the individual changes may be classified as a particular reporting type, classification within a higher risk category may be warranted as a result of the composite effect of these changes. In all such cases, MAHs are advised to contact the Board prior to submission of the variation application to obtain guidance on classifying such changes.

3.1.1. Notifications

Notifications are changes that could have minimal or no adverse effects on the overall safety, efficacy and quality of the FPP. Such notifications do not require prior acceptance, but must notify the Board immediately after implementation (immediate notification (IN)), or within 12 months following implementation (annual notification (AN)) of the change.



It should be highlighted that an IN or AN may be rejected in specific circumstances with the consequence that the MAH must cease to apply the already implemented variation.

3.1.2. Annual notification (AN)


MAHs must satisfy themselves that they meet all of the prescribed conditions for the change. The change should be summarized as part of the notification but the indicated documentation is not required to be submitted. The documentation indicated for ANs should be available on request or at the time of inspection. ANs should be submitted to the Board within 12 months of implementation of the changes. For convenience MAHs may group several AN changes as a single submission.

3.1.3. Immediate notification (IN)

MAHs must satisfy themselves that they meet all of the prescribed conditions for the change and submit all required documentation with the notification application. Such changes can be implemented immediately at the time of submission and they can be considered accepted if an objection is not issued by the Board within 30 calendar days of the date of acknowledgement of receipt of the application.

3.1.4. Minor variation (Vmin)

Minor variations are changes that may have minor effects on the overall safety, efficacy and quality of the FPP. MAHs must satisfy themselves that they meet all of the prescribed conditions for the change and submit all required documentation with the variation application.



Such variations can be implemented if no objection letter has been issued within a time period indicated on the Board's web site. Should questions arise during the specified period, the change can only be implemented on receipt of a letter of acceptance from the Board.

3.1.5. Major variation (Vmaj)


Major variations are changes that could have major effects on the overall safety, efficacy and quality of the FPP. The documentation required for the changes included in this reporting type should be submitted. Prior acceptance by the Board is required before the changes can be implemented. A letter of acceptance will be issued for all major variations if and when the variation is considered acceptable.

3.1.6. New applications and extension applications

Certain changes are so fundamental that they alter the terms of the accepted dossier and consequently cannot be considered as changes. In these cases a new dossier must be submitted. Examples of such changes are listed in Appendix 1.

3.1.7. Labelling information

For any change to labelling information (SmPC, PIL, labels) not covered by the variation categories described in this document, the Board must be notified and submission of the revised labelling information is expected as per the guidance on the Board's web site.



3.2. Conditions to be fulfilled.

For each variation, attempts have been made to identify particular circumstances where lower reporting requirements (IN, AN or Vmin) are possible. A change that does not meet all of the conditions stipulated for these specific circumstances is considered to be a Vmaj.

In some circumstances Vmaj categories have been specifically stated for a given variation. This has been done to indicate to MAHs what documents should be provided. This is for informational purposes only. The list of documentation is not intended to be comprehensive and further documentation may be required. For all changes it remains the responsibility of the MAH to provide all necessary documents to demonstrate that the change does not have a negative effect on the safety, efficacy and quality of the FPP.


3.3. Application and documentation required

Examples of variations are organized according to the structure of the CTD. For each variation, certain documents have been identified as supporting data and are organized according to CTD structure. Regardless of the documents specified, MAHs should ensure that they have provided all relevant information to support the variation.

Where applicable, the following should be included in the application:

- 1. A variation application form (a template can be downloaded from the Pharmacy Board's web site). All sections of this form should be completed and the document signed. Electronic versions of the application form, both as a Word document and a scanned signed PDF, should be provided in addition to the printed version;
- 2. An updated quality information summary (QIS) (if applicable);





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

3. Replacement of the relevant sections of the dossier as per CTD format;

4. Copies of SmPC, PIL and labels, if relevant (when a variation leads to a revision of the summary of product characteristics (SmPC), the patient information leaflet (PIL), or the labelling, the updated product information should be submitted as part of the application.

It should be noted that <PBSL> reserves the right to request further information not explicitly described in this guideline.

The QIS provides a summary of the key quality information from the product dossier. For FPPs that have an agreed-upon QIS, the QIS should be revised and submitted (in Word format only) with every variation application. Any revised sections within the QIS should be highlighted. If there is no change to the QIS as a result of the variation, a statement should be made in the covering letter to this effect.

Alternative approaches to the principles and practices described in this document may be acceptable provided they are supported by adequate scientific justification. It is also important to note that <PBSL> may request information or material, or define conditions not specifically described in this guidance, in order to adequately assess the safety, efficacy and quality of an FPP.

THE REPROPERTY	Title: Guideline on Variation	THARMACY BOARD OF AND OF THE ALTH SI SAMILED OF HEALTH SI SAMILED
Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

4. Administrative changes and changes to a CEP or to a confirmation of API-prequalification document

4.1. Change in the name and/ or corporate address of the MAH of the FPP.


Description of Change	Conditions	Documentation	Reporting
	to be fulfilled	required	Туре
1Change in the	1	1	IN
name and/ or			
corporate address			
of the MAH of the			
FPP.			

Conditions to be fulfilled

1. Confirmation that the MAH of the product remains the same legal entity.

Documentation required

1. A formal document from a relevant official body (e.g., the national medicines regulatory authority (PBSL)) in which the new name and/or address is mentioned.



4.2. Change in the name or address of a manufacturer of an API

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
2Change in the name or address of a manufacturer of an API.	1	1 - 2	IN

Conditions to be fulfilled


1. No change in the location (e.g. postcode, street name) of the manufacturing site and in the manufacturing operations.

Documentation required

- **1.**A formal document from a relevant official body (e.g. PBSL) in which the new name and/or address is mentioned.
- 2.An updated Letter of Access in case of change in the name of the holder of the APIMF

4.3. Change in the name and/or address of a manufacturer of the FPP

Description	of Cha	ange	Conditions to be fulfilled	Documentation required	Reporting Type
3Change name	in an	the d/or			



address of a manufacturer of the FPP

1 IN

Conditions to be fulfilled

1. No change in the location of the manufacturing site and in the manufacturing operations.


Documentation required

1.Copy of the modified manufacturing authorization or a formal document from a relevant official body (e.g., PBSL) in which the new name and/or address is mentioned

4.4. Deletion of a manufacturing site or manufacturer

1

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
4Deletion of a manufacturing site or manufacturer involving:			
4a production of the API starting material	1	1	AN



4b production or testing of the API 1 - 2 intermediate or API	1	IN
4c production, packaging or testing of the intermediate 1 - 2 or FPP	1	IN

Conditions to be fulfilled

- 1.At least one other site continues to perform the same function(s) as the site(s) intended to be deleted.
- 2.The deletion of the site is not a result of critical deficiencies in manufacturing

Documentation required

1.Clear identification of the manufacturing, packaging and/or testing site to be deleted, in the letter accompanying the application.

4.5. Submission of a new or updated CEP for an API or starting material or intermediate used in the manufacturing process of the API

Description of Change	Conditions	Documentation	Reporting
	to be fulfilled	required	Type





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

5Submission of a new or updated CEP for an API or starting material or

manufacturing

intermediate

process of the API:

used the

5a.1 from a currently accepted Manufacturer	1-5	1-5	AN
5a.2 from a currently accepted Manufacturer	1-4	1-6	IN
5a.3 from a currently accepted Manufacturer	1, 3 - 4	1 - 6	Vmin
5b.1 from a new manufacturer	1 - 4	1 - 6	IN
5b.2 from a new manufacturer	1 - 4	1 - 6	Vmin

Conditions to be fulfilled

- 1.No change in the FPP release and shelf-life specifications.
- 2.Unchanged (excluding tightening) additional (to Ph. Eur.) specifications for any impurities including organic, inorganic and genotoxic impurities and residual solvents, with the exception of residual solvents when the limits stipulated comply with ICH requirements.





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


3.The manufacturing process of the API, starting material or intermediate does not include the use of materials of human or animal origin for which an assessment of viral safety data is required.

4.For low solubility APIs the polymorph is the same, and whenever particle size is critical (including low solubility APIs) there is no significant difference in particle size distribution, compared to the API lot used in the preparation of the biobatch.

5. No revision of the FPP manufacturer's API specifications is required.

Documentation required

- **1.**Copy of the current (updated) CEP, including any annexes and a declaration of access for the CEP to be duly filled out by the CEP holder on behalf of the FPP manufacturer or MAH to the <NMRA> who refers to the CEP.
- **2.**A written commitment that the MAH will inform <PBSL> in the event that the CEP is withdrawn and an acknowledgement that withdrawal of the CEP will require additional consideration of the API data requirements to support the product dossier.
- **3.**Replacement of the relevant pages of the dossier with the revised information for the CEP submission option stipulated under section 3.2.S of the <PBSL <quote respective Guidelines on submission of documentation for marketing authorization: quality part>.
- **4.**(S.2.5) For sterile APIs, data on the sterilization process of the API, including validation data.
- **5.**(P.8.2) In the case of the submission of a CEP for an API, if the quality characteristics of the API are changed in such a way that it may impact the stability of the FPP, a commitment to



put under stability one batch of the FPP of at least pilot-scale, and to continue the study throughout the currently accepted shelf-life and to immediately report any out-of-specification results to <PBSL>.

6.(S.4.1) Copy of FPP manufacturer's revised API specifications.

4.6. Submission of a new or updated confirmation of API-prequalification


Description	of Condition	s to Documentation	Reporting
Change	be fulfille	d required	Туре

6.Submission of a new or updated confirmation of API-prequalification

document

6a.1 from a currently accepted manufacturer	1 – 3	1 - 3, 5	AN
6a.2 from a currently accepted manufacturer	1 - 2	1 - 5	V _{min}





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:
2024		Registrar


	from facturer	new	1 – 3	1 - 3, 5	IN
	from	new	1 - 2	1 - 5	V _{min}
manu	facturer				

Conditions to be fulfilled

- 1. No change in the FPP release and shelf-life specifications.
- 2.For low solubility APIs the API polymorph is the same, and whenever particle size is critical (including low solubility APIs) there is no significant difference in particle size distribution, compared to the API lot used in the preparation of the biobatch.
- 3. There is no difference in impurity profile of the proposed API to be supplied, including organic, inorganic, genotoxic impurities and residual solvents, compared to that of the API currently supplied. The proposed API manufacturer's specifications do not require the revision of the FPP manufacturer's API specifications.

Documentation required

- 1.Copy of the current (updated) confirmation of API-PQ document. The API manufacturer should duly fill out the authorization box with the name of the MAH or FPP manufacturer seeking to use the document.
- 2.Replacement of the relevant pages of the dossier with the revised information for the API-PQ procedure submission option (Option 1: confirmation of API Prequalification document) stipulated under section 3.2.S. of the <PBSL> <quote respective Guidelines on submission of documentation for marketing authorization: quality part>.
- 3.(S.2.5) For sterile APIs, data on the sterilization process of the API,



including validation.


4.(S.4.1) Copy of FPP manufacturer's revised API specifications.

5.(P.8.2) If the quality characteristics of the API are changed in such a way that it may impact the stability of the FPP, a commitment to put under stability one batch of at least pilot-scale of the FPP and to continue the study throughout the currently accepted shelf-life and to immediately report any out-of-specification results to <PBSL>.

4.7. Submission of a new or updated transmissible spongiform encephalopathy (TSE) CEP for an excipient or API (addition or replacement).

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
7.Submission of a new or updated transmissible spongiform encephalopathy (TSE) CEP for an excipient or API (addition or replacement).			
	None	1	IN





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

Conditions to be fulfilled

None

Documentation required

1.Copy of the current updated TSE (CEP)

5. Quality Changes

5.1. Active Pharmaceutical Ingredient

3.2.S API (or Drug Substance)

3.2.S.2 Manufacture


5.1.1. Replacement or addition of a new manufacturing site or manufacturer of an API

Description of Change	Conditions	Documentation	Reporting
	to be	required	Type
	fulfilled		

8.Replacement addition of a new manufacturing site or manufacturer of an API

involving;






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

8a.1API testing only	1, 2, 4	1, 3-4	IN
8a.2	2, 4	1, 3 -4	Vmin
8b.1 production of API starting material	3 – 4	changes are	required; such handled as the APIMF by er.
8b.2 production of API starting material	4 – 5	1-2, 12	IN
8b.3 production of API starting material	None	1,2,5, 7-8,12, 13	Vmaj
8c.1 production of API intermediate	3 - 4	changes are	required; such handled as the APIMF by the
8c.2 production of API intermediate	4, 6	1 - 2, 12	IN
8c.3 production of API intermediate	None	1 - 2, 5, 7 - 8, 12, 13	Vmaj
8d.1 production of API (APIMF procedure)	3, 7-9	1, 2, 6, 8	IN
8d.2 production of API (APIMF procedure)	3, 7, 9	1, 2, 6-8	Vmin
8e.1 production of API	1, 9 -11	1 - 2, 4, 8 - 9	IN





Rev No: 00	Doc No: PBSL/GL/0	026	Version no. 01
------------	-------------------	-----	----------------

Issue date: 15 May 2024 Approved by: 2024 Registrar


(full dossier)

8e.2 production of API	None	1, 2, 4, 5, 7–8, Vmaj
(full dossier)		10 - 11, 13

Conditions to be fulfilled

- 1.The API is non-sterile.
- 2. The transfer of analytical methods has been successfully undertaken.
- 3. The new site is supported by an APIMF that is currently accepted through the APIMF procedure and the FPP manufacturer holds a valid Letter of Access.
- 4. No change in the FPP manufacturer's API specifications.
- 5.The impurity profile of the API starting material is essentially the same as other accepted sources. The introduction of the new supplier does not require the revision of the API manufacturer's API starting material specifications. The route of synthesis is verified as identical to that already accepted.
- 6. Specifications (including in-process, methods of analysis of all materials), method of manufacture and detailed route of synthesis are verified as identical to those already accepted. The introduction of the new supplier does not require the revision of the API manufacturer's API intermediate specifications.
- 7. No change in the FPP release and end-of-shelf-life specifications.
- 8.No difference in impurity profile of the proposed API to be supplied, including organic, inorganic and genotoxic impurities and residual





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

solvents. The proposed API manufacturer's specifications do not require the revision of the FPP manufacturer's API specifications.

9.For low-solubility APIs the API polymorph is the same, and whenever particle size is critical (including low-solubility APIs) there is no significant difference in particle size distribution, compared to the API lot used in the preparation of the biobatch.


10. Specifications (including in-process controls, methods of analysis of all materials), method of manufacture (including batch size) and detailed route of synthesis are verified as identical to those already accepted (such situations are generally limited to additional sites by the same manufacturer or a new contract manufacturing site with evidence of an acceptable and similar quality system to that of the main manufacturer).

11. Where materials of human or animal origin are used in the process, the manufacturer does not use any new supplier for which assessment is required of viral safety or of compliance with the current WHO Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products (www.who.int/biologicals) or EMA's Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (www.emea.europa.eu/ema) or equivalent guidelines of the ICH region and associated countries.

Documentation required

1.(S.2.1) Name, address, and responsibility of the proposed site or facility involved in manufacture or testing (including block(s) and unit(s)). A valid testing authorization or a certificate of GMP compliance, if applicable.






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

- **2.**(S.2.2) A side-by-side comparison of the manufacturing flowcharts for production of the API, intermediate, or API starting material (as applicable) at the parent and proposed sites and a tabulated summary of the differences.
- **3.**(S.4.3) Copies or summaries of validation reports or method transfer reports, which demonstrate equivalence of analytical procedures to be used at the proposed testing site.
- **4.**(S.4.4) Description of the batches, copies of certificates of analysis and batch analysis data (in a comparative tabular format) for at least two (minimum pilot- scale) batches of the API from the currently accepted and proposed manufacturers and/or sites.
- **5.**Relevant sections of (S) documentation in fulfilment of requirements for full information provided in the dossier under section 3.2.S of the WHO Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part.7
- **6.**The open part of the new APIMF (with a Letter of Access provided in Module 1) and documentation in fulfilment of requirements for the APIMF option under section 3.2.S of the <PBSL> <quote respective Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product>
- **7.**(P.8.2) If the quality characteristics of the API are changed in such a way that it may impact the stability of the FPP, a commitment to put under stability one production-scale batch of the FPP and to continue the study throughout the currently accepted shelf-life and to immediately report any out of





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

specification results to <PBSL>.

- **8.**(S.4.1) A copy of the FPP manufacturer's API specifications.
- **9.**(S.2) A declaration from the MAH of the prequalified FPP that the route of synthesis, materials, quality control procedures and specifications of the API and key (ultimate) intermediate in the manufacturing process of the API (if applicable) are the same as those already accepted.
- **10.**A discussion of the impact of the new API on the safety, efficacy and quality of the FPP.
- 11. For low solubility APIs where polymorphic form is different or whenever particle size is critical (including low-solubility APIs) where there is a significant difference in particle size distribution compared to the lot used in the biobatch, evidence the differences do not impact the quality bioavailability of the FPP.
- 12. Certificates of analysis for at least one batch of API starting material or intermediate (as applicable) issued by the new supplier and by the API manufacturer. Comparative batch analysis of final API manufactured using API starting material or intermediate (as applicable) from the new source and from a previously accepted source. For an alternative source of plantderived starting material, control of pesticide residues must be established. This can either be in the form of an attestation from the starting material supplier that no pesticides are used during the growth of the plant material, or by providing the results of pesticide screening from one batch of the starting material.

THE REEDON TORS	Title: Guideline on Variation	TANK THE REAL LE ON THE OF HEALTH & S.
Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

13.An analysis of the impact of the change in supplier with respect to the need for API stability studies and a commitment to conduct such studies if necessary.


5.1.2. Change or addition of a manufacturing block or unit at a currently accepted site of API manufacture

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
9 change or addition of a manufacturing block or unit at a currently accepted site of API manufacture			
9a	1 - 5	No variation is rechanges are amendments to the the APIMF holder.	handled as
9b	1, 3 - 5	1 – 4 I	N

Conditions to be fulfilled

- 1. The API is non-sterile.
- 2. The API manufacturing block or unit is currently accepted through the





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


2027

APIMF procedure.

- 3.The same quality system covers currently accepted and proposed units or blocks.
- 4.For low-solubility APIs, there is no change in the polymorphic form and whenever particle size is critical (including low solubility APIs) there is no significant change to the particle size distribution compared to the API lot used in the preparation of the biobatch.
- 5.No change in the route of synthesis, quality control procedures and specifications of the API and key (ultimate) intermediate in the manufacturing process of the API (if applicable). Minor changes in the equipment are acceptable.

Documentation required

- 1.(S.2) A declaration from the MAH of the FPP that the route of synthesis, quality control procedures and specifications of the API and key (ultimate) intermediate in the manufacturing process of the API (if applicable) are the same as those already accepted.
- **2.**(S.2.1) Name, address, and responsibility of the proposed production site or facility involved in manufacturing and/or testing (including block(s) and unit(s)). A valid manufacturing and/or testing authorization and a certificate of GMP compliance, if available.
- **3.**(S.4.4) Description of the batches, copies of certificates of analysis and batch analysis data (in a comparative tabular format) for at least two (minimum pilot-scale) batches of the API from the




currently accepted and proposed units or blocks.

4.(S.2.2) A summary of differences between manufacture and control of the API at the currently accepted and proposed units or blocks, if applicable.

5.1.3. Change in the manufacturing process of the API

Description of Change		Documentation required	Reporting Type
10 change in the manufacturing process of the API			
10a change in the manufacturing process of the API	1 - 3, 9	·	AN
10b1 change in the manufacturing process of the API	9		
10b2 change in the manufacturing process of the API	1 - 2, 4, 6 - 8, 10	3 - 4, 11 - 12	Vmin
10c change in the manufacturing process of the API	1 - 2, 4 -7	3 - 4, 11 - 12	Vmin






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

10d None 2 – 14 Vmaj

Conditions to be fulfilled

- 1.No change in the physical state (e.g. crystalline, amorphous) of the API.
- 2.For low solubility APIs, there is no change in the polymorphic form and whenever particle size is critical (including low solubility APIs) there is no significant change in the particle size distribution compared to that of the API lot used in the preparation of the biobatch.
- 3. The API manufacturing site is currently accepted through the APIMF procedure.
- 4. Where materials of human or animal origin are used in the process, the manufacturer does not use any new process for which assessment of viral safety data or TSE risk assessment is required.
- 5.No change in the route of synthesis (i.e. intermediates remain the same) and there are no new reagents, catalysts or solvents used in the process.
- 6.No change in qualitative and quantitative impurity profile or in physicochemical properties of the API.
- 7. The change does not affect the sterilization procedures of a sterile API.
- 8. The change involves only steps before the final intermediate.
- 9. The change does not require revision of the starting material,





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


intermediate or API specifications.

10. The change does not require revision of the API specifications.

Documentation required

- **1.**A copy of the APIMF amendment acceptance letter.
- **2.**(P.8.2) If the quality characteristics of the API are changed in a way that may impact the stability of the FPP, a commitment to put under stability one production-scale batch of the FPP and to continue the study throughout the currently accepted shelf-life and to immediately report any out of specification results to <PBSL>.
- **3.**(S.2.2) A side-by-side comparison of the current process and the new process.
- **4.**(S.2.2) A flow diagram of the proposed synthetic process(es) and a brief narrative description of the proposed manufacturing process(es).
- **5.**(S.2.3) Information on the quality and controls of the materials (e.g., raw materials, starting materials, solvents, reagents, catalysts) used in the manufacture of the proposed API, where applicable
- **6.**(S.2.3) Either a TSE CEP for any new source of material or, where applicable, documented evidence that the specific source of the material that carries a risk of TSE has previously been assessed by the <PBSL> and shown to comply with the current WHO guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


y Effective date: 17 May 2024 Approved by: Registrar

Issue date: 15 May

2024

(www.who.int/biologicals) or EMA's Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (www. emea.europa.eu/ema) or equivalent guidelines of the ICH region and associated countries.

- **7.**(S.2.4) Information on controls of critical steps and intermediates, where applicable.
- **8.**(S.2.5) Evidence of process validation and/or evaluation studies for sterilization, if applicable.
- **9.**(S.3.1) Evidence for elucidation of structure, where applicable.
- **10.**(S.3.2) Information on impurities.
- **11.**(S.4.1) A copy of currently accepted specifications of API (and starting material and intermediate, if applicable).
- **12.**(S.4.4) Description of the batches, certificates of analysis or batch analysis report, and summary of results, in a comparative tabular format, for at least two batches (minimum pilot-scale) manufactured according to the current and proposed processes.
- **13.**(S.7.1) Results of two batches of at least pilot-scale with a minimum of three months of accelerated (and intermediate as appropriate) and three months of long-term testing of the proposed API.
- **14.**For low-solubility APIs where the polymorphic form has changed or whenever particle size is critical (including low-solubility APIs) where there is dissimilar particle size distribution



compared to the lot used in the biobatch, evidence that the differences do not impact the quality and bioavailability of the FPP.

5.1.4. Change in the in-process tests or limits applied during the manufacture of the API

Description of Change		Documentation required	Reporting Type
11Change in the in- process tests or limits applied during the manufacture of the API:			
11a any change in the manufacturing process controls	1	No variation is changes are amendments to the APIMF holder.	handled as the APIMF by
11b tightening of in process Limits	2 - 4	1	AN
11c addition of a new in-process test and limit	2 - 5	1 - 5	AN






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
------------	---------------------	----------------

Issue date: 15 May 2024 Approved by: 2024 Registrar

11d addition or replacement of an in – process test as a result of a safety or quality issue	None	1 - 5, 7, 8 - 10
11e1 deletion of an in – process test	2, 6 - 7	1 – 3, 6 AN
11e2 deletion of an in – process test	None	1 -3, 5, 7 - 10
11f relaxation of the in-process test limits	None	1–3, 5, Vmaj 7–10

- 1.API manufacturing site is currently accepted through the APIMF procedure.
- 2.The change is not necessitated by unexpected events arising during manufacture e.g., a new unqualified impurity or a change in total impurity limits.
- 3. The change is within the range of currently accepted limits.
- 4. The analytical procedure remains the same, or changes to the analytical procedure are minor.
- 5. Any new analytical procedure does not concern a novel non-standard technique or a standard technique used in a novel way.
- 6. The affected parameter is non-significant.
- 7. The change does not affect the sterilization procedures of a sterile






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

API.

- **1.**A comparison of the currently accepted and the proposed inprocess tests.
- **2.**(S.2.2) Flow diagram of the proposed synthetic process(es) and a brief narrative description of the proposed manufacturing process(es).
- **3.**(S.2.4) Information on the controls performed at critical steps of the manufacturing process and on intermediates of the proposed API.
- **4.**Details of any new non-pharmacopoeia analytical method and validation data where relevant.
- **5.** Justification for the new in-process test and/or limits.
- **6.** Justification and/or risk-assessment showing that the parameter is non-significant.
- **7.**(S.2.5) Evidence of process validation and/or evaluation studies for sterilization, where applicable.
- **8.**(S.3.2) Information on impurities, if applicable.
- **9.**(S.4.1) Copy of currently accepted specifications of API (and intermediates, if applicable).
- **10.**(S.4.4) Description of the batches, certificates of analysis or batch analysis report and summary of results, in a comparative




tabular format, for at least two batches (minimum pilot-scale) for all specification parameters.

5.1.5. Change in batch size of the API or intermediate involving

Description of Change		Documentation required	Reporting Type
12Change in batch size of the API or intermediate involving:			
12a up to 10-fold compared to the currently accepted batch size	1 - 2, 4, 6	1, 3- 4	AN
12b1 Downscaling	1 - 4	1, 3- 4	AN
12b2 Downscaling	1 – 3	1 – 4	IN
12c any change in scale (APIMF procedure)	5	1-2, 4-5	AN
12d more than 10-fold increase compared to the currently accepted	1-2, 4, 6	1, 3-4	Vmin





Rev No: 00 Doc No: PE		
Issue date: 15 May Effective d	Approved by:	

batch size

Conditions to be fulfilled

1.No changes to the manufacturing process other than those necessitated by

changes in scale (e.g., use of a different size of equipment).

- 2. The change does not affect the reproducibility of the process.
- 3. The change is not necessitated by unexpected events arising during manufacture or due to stability concerns.
- 4. The change does not concern a sterile API.
- 5.The API manufacturing site and batch size is currently accepted through the APIMF procedure.
- 6. The proposed batch size increase is relative to either the originally accepted batch size, or the batch size accepted through a subsequent major or minor variation

- **1.**(S.2.5) Where applicable, evidence of process validation and/or evaluation studies for sterilization.
- **2.**(S.4.1) Copy of the currently accepted specifications of the API (and of the intermediate, if applicable).
- **3.**(S.4.4) Batch analysis data (in tabular format) issued by the FPP manufacturer for a minimum of two batches each of the

THE REPROSTURE	Title: Guideline on Variation	THARMACY BOARD OF AND OF AND OF HEALTH & SAMTHOD
Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar


currently accepted batch size and the proposed batch size.

4.A copy of the APIMF amendment acceptance letter

5.1.6. Change or addition of a manufacturing block or unit at a currently accepted site of API manufacture

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
13change or addition of a manufacturing block or unit at a currently accepted site of API manufacture			
13a any change	1	No variation is changes are amendments to the APIMF holder	handled as the APIMF by
13b tightening of the specification limits	2-4	1-3	AN
13c minor change to an analytical procedure	5–7	2–3	AN






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01

Issue date: 15 May 2024 Approved by: Registrar

13d addition of a new specification parameter and a corresponding analytical procedure where necessary	2, 7 - 9	1 -3	AN
13e deletion of a specification parameter or deletion of an analytical procedure	2, 10	1 - 4	AN
13f addition or replacement of a specification parameter as a result of a safety or	None	1 - 3, 5	Vmin
quality issue 13g relaxation of the currently accepted specification limits for solvents, reagents, catalysts and raw Materials	4, 7, 9–10	1, 3-4	IN
13h relaxation of the currently accepted specification limits for API starting materials	None	1 - 3, 5	Vmaj





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
------------	---------------------	----------------

Issue date: 15 May 2024 Approved by: 2024 Registrar

and


Intermediates

- 1.API manufacturing site is currently accepted through the APIMF procedure.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3. Any change is within the range of currently accepted limits.
- 4. The analytical procedure remains the same.
- 5. The method of analysis is based on the same analytical technique or principle (e.g. changes to the analytical procedure are within allowable adjustments, to column length and other parameters, but do not include variations beyond the acceptable ranges or a different type of column and method).
- 6.Appropriate validation studies have been performed in accordance with the relevant guidelines and show that the updated analytical procedure is at least equivalent to the former analytical procedure.
- 7.No change to the total impurity limits; no new impurities are detected.
- 8. Any new analytical procedure does not concern a novel non-standard technique or a standard technique used in a novel way.
- 9. The change does not concern a genotoxic impurity.



2024

Title: Guideline on Variation



Registrar

Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Tesue date: 15 May	Effective date: 17 May 2024	Approved by:


10. The affected parameter is non-significant or the alternative analytical procedure

has been previously accepted.

- **1.**Comparative table of currently accepted and proposed specifications.
- **2.**(S.2.3) Information on the quality and controls of the materials (e.g. raw materials, starting materials, solvents, reagents, catalysts) used in the manufacture of the proposed API, where applicable.
- **3.**(S.2.4) Information on intermediates, where applicable.
- **4.** Justification and/or risk assessment showing that the parameter is non-significant.
- **5.**(S.3.2) Information on impurities, where applicable.
- 3.2. S.4 Control of the API by the API manufacturer
- 5.1.7. Changes to the test parameters, acceptance criteria, or analytical procedures of the API manufacturer that do not require a change to the FPP manufacturer's API specifications involving

Description of Change	Condition	S	Documentation	Reporting
	to fulfilled	be	required	Туре





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


Issue date: 15 May 2024 Approved by: 2024 Registrar

14Changes to the test parameters, acceptance criteria, or analytical procedures of the API manufacturer that do not require a change to the FPP manufacturer's API specifications involving

14a API supported through the APIMF 1 - 2 procedure	changes are	required; such handled as the associated
14b API not supported through the APIMF 2 procedure.	1 - 4	IN

- 1.The revised test parameters, acceptance criteria, or analytical procedures have been submitted as amendments to the associated APIMF and accepted.
- 2.The API manufacturer has provided the relevant documentation to the FPP manufacturer. The FPP manufacturer has considered the API manufacturer's revisions and determined that no consequential revisions to the FPP manufacturer's API test parameters, acceptance criteria, or analytical procedures are required to ensure that adequate control of





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

the API is maintained.

Documentation required


- **1.**(S.4.1) Copy of the current and proposed API specifications dated and signed by the API manufacturer.
- **2.**(S.4.2) Copies or summaries of analytical procedures, if new analytical procedures are used.
- **3.**(S.4.3) Copies or summaries of validation reports for new or revised analytical procedures, if applicable.
- **4.**Justification as to why the change does not affect the FPP manufacturer's specifications.

3.2. S.4 Control of the API by the FPP manufacturer

5.1.8. Change to the test parameters or acceptance criteria of the API specifications of the FPP manufacturer

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
15Change to the test parameters or acceptance criteria of the API specifications of the EPP manufacturer			





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: Registrar

involvina:

involving:			
parameter or acceptance criterion controlled in compliance with an officially recognized pharmacopoeial monograph as a result of an update to this monograph to which the API is controlled.	11	1 - 5	AN
15b1 deletion of a test parameter	1 - 2	1, 6	AN
15b2 deletion of a test parameter	10	1, 6, 8	IN
15b3 deletion of a test parameter	None	1, 6	Vmaj
15c1 addition of a test parameter	1, 4 - 8	1 - 6	AN
15c2 addition of a test parameter	1, 5 - 6, 10	1 - 6, 8	IN
15c3 addition of a test parameter	1, 5 - 6	1 - 6	Vmin
15c4 addition of a test parameter	None	1 - 7	Vmaj





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar


15d1 replacement of a test parameter	1, 5 - 8	1 - 6	IN
15d2 replacement of a test parameter	5, 7, 10	1 - 6, 8	Vmin
15d3 addition of a test parameter	None	1 - 7	Vmaj
15e1 tightening of an acceptance criterion	1, 3, 9	1,6	AN
15f1 relaxation of an acceptance criterion	1, 5 - 9	1,6	IN
15f2	5, 7, 10	1, 6, 8	Vmin
15f3	None	1, 6 - 7	Vmaj

- 1. The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 2. The deleted test has been demonstrated to be redundant with respect to the remaining tests.
- 3. The change is within the range of currently accepted acceptance criteria.
- 4. Any new analytical procedure does not concern a novel, non-standard



2024

Title: Guideline on Variation



Registrar


Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:

technique or a standard technique used in a novel way.

- 5.For insoluble APIs there is no change in the polymorphic form and whenever particle size is critical (including low-solubility APIs) there is no change in particle size distribution acceptance criteria.
- 6. No additional impurity found over the ICH identification threshold.
- 7. The change does not concern sterility testing.
- 8. The change does not involve the control of a genotoxic impurity.
- 9. The associated analytical procedure remains the same.
- 10. The change has resulted from a revision of the API manufacturer's specifications and is accepted as part of an APIMF amendment.
- 11. No change is required in FPP release and shelf-life specifications.

- 1.(S.4.1) A copy of the proposed API specifications (of the FPP manufacturer) dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications. In addition, if the change has resulted from a revision to the API manufacturer's specifications, a copy of the API specifications (of the API manufacturer) dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- **2.**(S.4.2) Copies or summaries of analytical procedures, if new analytical procedures are used.
- **3.**(S.4.3) Copies or summaries of validation or verification reports






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

issued by the FPP manufacturer, if new analytical procedures are used.


- **4.**(S.4.3) Where an in-house analytical procedure is used and a pharmacopoeial standard is claimed, results of an equivalence study between the in-house and pharmacopoeial methods.
- **5.**(S.4.4) Description of the batches, certificates of analysis or batch analysis report, and summary of results in tabular format, for at least one batch if new tests and/or analytical methods are implemented.
- **6.**(S.4.5) Justification of the proposed API specifications (e.g. test parameters, acceptance criteria, or analytical procedures).
- 7.(P.2) Where changes have occurred to the particle size criteria of an insoluble API or wherever particle size is critical, evidence is provided that the changes do not affect the in vitro release properties and bioavailability of the FPP. In general, it is sufficient to provide multipoint comparative dissolution profiles (in three media covering the physiological range (pH 1.2 or (0.1N HCl), 4.5 and 6.8) without surfactant) for one batch of FPP manufactured using API that meets the proposed criteria; one batch of FPP manufactured using API that meets the currently accepted criteria; and data on the FPP batch used in the registration bioequivalence study. However, if the routine dissolution medium contains a surfactant, the MAH should contact <PBSL> for advice. For changes to the polymorph of an insoluble API the supplier should contact <PBSL> for advice before embarking upon any investigation.
- **8.**Copy of the APIMF amendment acceptance letter.



5.1.9. Change to the analytical procedures used to control the API by the FPP manufacturer

Description of Change		Documentation required	Reporting Type
16Change to the analytical procedures used to control the API by the FPP manufacturer involving:			
16a change in an analytical procedure as a result of a revision to the officially recognized pharmacopeial monograph to which the API is controlled	None	1 - 3	AN
16b change from a currently accepted in-house analytical procedure to an analytical	None	1 - 4	IN





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

procedure officially in an recognized pharmacopoeia or from the analytical procedure in officially one recognized pharmacopoeia to an analytical procedure in another official recognized Pharmacopoeia 1-3 ΑN 1-3 16c.1 addition of an analytical Procedure 3, 8 1-3, 5 ΑN 16c.2 1-3, 5 8 Vmin 16c.3 Vmaj 1-3 None 16c.4 1-6 1-4 ΑN 16d.1 modification or replacement of an analytical procedure





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar


16d.2	2-3, 5-6, 8	1-5	AN
16d.3	1-3, 5-6	1-4	Vmin
16d.4	5-6, 8	1-5	Vmin
16d.5	None	1-4	Vmaj
16e.1 deletion of an analytical procedure	6-7	1, 6	AN
16e.2	6, 8	1, 5, 6	IN
16e.3	None	1, 6	Vmaj

- 1. Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3.No new impurities have been detected as a result of the use of the new analytical method.
- 4. The method of analysis is based on the same analytical technique or principle (e.g. changes to the analytical procedure are within allowable adjustments to column length and other parameters, but do not include variations beyond the acceptable ranges or a different type of column



2024

Title: Guideline on Variation




Registrar

Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:

and method), and no new impurities are detected.

- 5. Comparative studies are available demonstrating that the proposed analytical procedure is at least equivalent to the currently accepted analytical procedure.
- 6. The change does not concern sterility testing.
- 7. The deleted analytical procedure is an alternative method and is equivalent to a currently accepted method.
- 8. The new or modified analytical method is identical to that used by the API manufacturer and has been accepted as part of an amendment to the associated APIMF.

- **1.**(S.4.1) Copy of the proposed API specifications dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- **2.**(S.4.2) Copies or summaries of analytical procedures if new or significantly modified analytical procedures are used.
- **3.**(S.4.3) Copies or summaries of validation or verification reports issued by the FPP manufacturer if new or significantly modified analytical procedures are used.
- **4.**(S.4.4) Comparative analytical results demonstrating that the proposed analytical procedures are at least equivalent to the accepted analytical procedures.
- **5.**A copy of the APIMF acceptance letter.



6.(S.4.5) Justification for the deletion of the analytical procedure, with supporting data.

THE REPROSTURE	Title: Guideline on Variation	THARMACY BOARD OF AND OF AND OF HEALTH & SAMTHOD
Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

3.2.S.6 Container Closure System


5.1.10. Change or addition of a manufacturing block or unit at a currently accepted site of API manufacture

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
17Change or addition of a manufacturing block or unit at a currently accepted site of API manufacture			
17a Change in the immediate packaging (primary and components) for storage	3, 4	1 - 2, 4	AN
17b Change in the immediate packaging (primary and components) for storage	1-2, 4	2-3	IN
17c Change in the immediate packaging	4	1-3	Vmin



2024

Title: Guideline on Variation



Registrar


Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:

(primary and components) for storage

Conditions to be fulfilled


- 1.Results demonstrate that the proposed primary packaging type is at least equivalent to the currently accepted primary packaging type with respect to its relevant properties (e.g. including results of transportation or interaction studies, and moisture permeability among others).
- 2. The change does not concern a sterile API.
- 3. The change has previously been accepted through the APIMF procedure.
- 4. The change is not the result of stability issues.

- **1.**(S.2.5) Evidence of process validation and/or evaluation studies for sterilization if different from the current process.
- **2.**(S.6) Information on the proposed primary packaging (e.g., description and specifications) and data in fulfillment of condition 1.
- **3.**(S.7.1) Results of (or a commitment to study in the case of demonstrated equivalent or more protective packaging) a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing of the API in the proposed primary packaging type.
- **4.**A copy of the APIMF amendment acceptance letter.



5.1.11. Change in the specifications of the immediate packaging for the storage and shipment of the API

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
18Change in the specifications of the immediate packaging for the storage and shipment of the API involving:			
18a tightening of specification limits	1 - 2	1	AN
18b addition of a test parameter	2 - 3	1 - 3	AN
18c deletion of a non- critical parameter	2	1, 4	AN
18d any change (APIMF procedure)	4	changes are	required; such handled as the associated



Conditions to be fulfilled


- 1. The change is within the range of currently accepted limits.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3. Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 4.The change has previously been accepted through the APIMF procedure.

Documentation required

- **1.**(S.4.5) Comparative table of currently accepted and proposed specifications, justification of the proposed specifications.
- **2.**(S.4.2) Details of method and summary of validation of new analytical procedure.
- **3.**(S.6) Certificate of analysis for one batch.
- **4.** Justification to demonstrate that the parameter is not critical.

5.1.12. Change to an analytical procedure on the immediate packaging of the API

Description of Change	Conditions	Documentation	Reporting




	to b fulfilled	oe required	Туре
19Change to an analytical			
procedure on the immediate			
packaging of the API involving:			
19a minor change to an analytical procedure	1 - 3	1.	AN
19b other changes to an			
analytical procedure including addition or replacement of an analytical procedure	2-4	1	AN
19c deletion of an analytical Procedure	5	2	AN
19d any change (APIMF procedure)	6	No variation is changes are amendments to APIMF	handled as

Conditions to be fulfilled

1. The method of analysis is based on the same analytical technique or





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


principle (e.g. changes to the analytical procedure are within allowable adjustments to column length and other parameters, but do not include variations beyond the acceptable ranges or a different type of column and method).

- 2.Appropriate (re)validation studies have been performed in accordance with the relevant guidelines.
- 3.comparative studies indicate the new analytical procedure to be at least equivalent to the currently accepted procedure.
- 4. Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 5. The deleted analytical procedure is an alternative method and is equivalent to a currently accepted method.
- 6.The change has previously been accepted through the APIMF procedure.

Documentation required

- **1.**(S.6) Comparative validation results demonstrating that the currently accepted and proposed procedures are at least equivalent.
- **2.** Justification for deletion of the analytical procedure.

3.2.S.7 Stability



5.1.13. Change in the retest period or shelf-life of the API involving

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
20Change in the retest period or shelf-life of the API involving:			
20a any change (APIMF procedure)	4	4	IN
20b reduction	3	1-2	IN
20c extension	1-2	1-3	Vmin

- 1.No change to the primary packaging in direct contact with the API or to the recommended condition of storage.
- 2.Stability data were generated in accordance with the currently accepted stability protocol.
- 3. The change is not necessitated by unexpected events arising during manufacture or because of stability concerns.
- 4. The revised retest period has previously been accepted through the APIMF procedure.

TURIO REPROMINE	Title: Guideline on Variation	THARPACY BOARD OF AND OF THE ALTH & SAMPAND OF HEALTH & SAMPAND OF H
Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

Documentation required

- **1.**(S.7.1) Proposed retest period or shelf-life, summary of stability testing according to currently accepted protocol and test results.
- **2.**(S.7.2) Updated post-acceptance stability protocol and stability commitment and justification of change, when applicable.
- **3.**(S.7.3) Stability data to support the change.
- **4.**A copy of the APIMF acceptance letter.

5.1.14. Change in the labelled storage conditions of the API involving

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
21Change in the labelled storage conditions of the API involving:			
21a any change in storage conditions (APIMF procedure)	1	1	IN
21b any change in storage conditions	2	2	Vmin





Version no. 01 Rev No: 00 Doc No: PBSL/GL/026


Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

Conditions to be fulfilled

- 1. The revised storage conditions have previously been accepted through the APIMF procedure.
- 2. The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns

- **1.**A copy of the APIMF acceptance letter.
- 2.(S.7.1) Stability and/or compatibility test results to support the change to the storage conditions.




5.2. Finished Pharmaceutical Product (FPP) or drug product

3.2. P.1 Description and composition of the FPP

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
22a Change in the composition of a solution dosage form	1 - 6	2, 4, 7, 9–10	IN
22b	None	1 - 10	Vmaj

- 1. The affected excipient(s) does/do not function to affect the solubility and/or the absorption of the API.
- 2.The affected excipient(s) does/do not function as a preservative or preservative enhancer.
- 3. No change in the specifications of the affected excipient(s) or the FPP.
- 4.No change in the physical characteristics of the FPP (e.g., viscosity, osmolality, pH).
- 5. The change does not concern a sterile FPP.
- 6.The excipients are qualitatively the same. The change in the amount (or concentration) of each excipient is within $\pm 10\%$ of the amount (or





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: Registrar


concentration) of each excipient in the originally prequalified product.

- **1.**Supporting clinical or comparative bioavailability data or justification for not submitting a new bioequivalence study according to the current <NMRA> guidelines on bioequivalence.
- **2.**(P.1) Description and composition of the FPP.
- **3.**(P.2) Discussion on the components of the proposed product (e.g., choice of excipients, compatibility of API and excipients, suitability studies on the packaging system for the changed product).
- **4.**(P.3) Batch formula, description of manufacturing process and process controls, controls of critical steps and intermediates, process validation protocol and/or evaluation.
- **5.**(P.4) Control of excipients, if new excipients are proposed.
- **6.**(P.4.5) If applicable, either a CEP for any new component of animal origin susceptible to TSE risk or, where applicable, documented evidence that the specific source of the TSE risk material has been previously assessed by an PBSL in the ICH region or associated countries and shown to comply with the scope of the current guidelines in the countries of the ICH region or associated countries. The following information should be included for each such material: name of manufacturer, species and tissues from which the material is derived, country of origin of the source animals, and use of the



2024

Title: Guideline on Variation



Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar


material.

- 7.(P.5) Copies of FPP release and shelf-life specifications and certificates of analysis for a minimum of two pilot- or production-scale batches. If applicable, data to demonstrate that the new excipient does not interfere with the analytical procedures for the FPP.
- 8.(P.8.1) Results of stability testing generated on at least two pilotor production- scale batches with a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing.
- 9.(P.8.2) Updated post-acceptance stability protocol and stability commitment to place the first production-scale batch of each strength of the proposed product into the long-term stability programme (bracketing and matrixing for multiple strengths and packaging components could be applied, if scientifically justified).
- **10.**(R.1) Copies of relevant pages of blank master production documents with changes highlighted, as well as relevant pages of the executed production document for one batch and confirmation that there are no changes to the production documents other than those highlighted

5.2.1. Change in the colouring system or the flavouring system currently used in the FPP involving

Description of Change	Conditions	Documentation	Reporting
	to	pe	





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

	fulfilled	required	Type
23Change in the colouring system or the flavouring system currently used in the FPP involving:			
23a reduction or increase of one or more components of the colouring or the flavouring system	1-3, 6	1, 4, 6–7	AN
23b deletion, addition or replacement of one or more components of the colouring or the flavouring system	1-6	1-7	IN
Conditions to be fulfilled			

- 1.No change in the functional characteristics of the pharmaceutical form e.g., disintegration time or dissolution profile
- 2. Any minor adjustment to the formulation to maintain the total weight is made using an excipient which currently makes up a major part of the FPP formulation.
- 3. Specifications for the FPP are updated only with respect to appearance, odour and/ or taste or if relevant, deletion or addition of a test for identification.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

- 4.Any new component must comply with section 3.2.P.4 of the <PBSL> <quote-respective Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product>.
- 5. Any new component does not include the use of materials of human or animal origin for which assessment of viral safety data is required, or is in compliance with the current WHO Guidelines on transmissible spongiform encephalopathies in biological and pharmaceutical relation to products (www.who.int/biologicals) or EMA's Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (www.emea.europa.eu/ema) or an equivalent guide from the ICH region and associated countries.
- 6.Where applicable, the change does not affect the differentiation between strengths and for paediatric formulations it does not require submission of results of taste acceptability studies.

Documentation required

- 1. Sample of the FPP.
- **2.**(P.2) Discussion on the components of the FPP (e.g. compatibility of API and qualitative composition of the colouring or flavouring system if purchased as a mixture, with specifications, if relevant).
- **3.**(P.4.5) Either a CEP for any new component of animal origin susceptible to TSE risk or, where applicable, documented evidence that the specific source of the TSE risk material

.






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

has been previously assessed by an PBSL in the ICH region or associated countries and shown to comply with the scope of the current guidelines in the countries of the ICH region or associated countries. The following information should be included for each such material: name of manufacturer, species and tissues from which the material is derived, country of origin of the source animals, and use of the material.

- **4.**(P.5) Copies of revised FPP release and shelf-life specifications and certificates of analysis for a minimum of two pilot- or production-scale batches.
- **5.**(P.5.3) If applicable, data to demonstrate that the new excipient does not interfere with the analytical procedures for the FPP.
- **6.**(P.8.1) Results of stability testing generated on at least two pilot- or production- scale batches with a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing.
- **7.**(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of the executed production documents for one batch and confirmation that there are no changes to the production documents other than those highlighted.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

5.2.2. Change in weight of tablet coatings or capsule shells involving

Description of Change	Conditions	Documentation	Reporting
	to be	required	Туре

24Change in weight of tablet coatings or capsule shells involving:

24a	immediate	1 - 3	2-5	AN
release oral	l FPPs			

24b gastro-resistant, modified or prolonged None 1 – 5 Vmaj release FPPs


Conditions to be fulfilled

1. Multipoint in vitro dissolution profiles of the proposed version of the product

(determined in the routine release medium on at least two batches of pilot- or

production-scale), are similar to the dissolution profiles of the biobatch.

- 2. Coating is not a critical factor for the release mechanism.
- 3. Specifications for the FPP are updated only with respect to weight and dimensions,



if applicable.

Documentation required

- 1.Justification for not submitting a new bioequivalence study according to the current <PBSL> guidelines on bioequivalence
- 2.(P.2) Comparative multipoint in vitro dissolution profiles in the routine release medium (or media), on at least two batches of pilot- or production-scale of the proposed product versus the biobatch.
- 3.(P.5) Copies of revised FPP release and shelf-life specifications and certificates of analysis for a minimum of one pilot- or production-scale batch.
- 4.(P.8.1) Results of stability testing generated on at least one pilot- or production- scale batch with a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing.
- (R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of the executed production documents for one batch and confirmation that there are no changes to the production documents other than those highlighted

5.2.3. Change in the composition of an immediate-release solid oral dosage form

Description of Change	Conditions	Documentation	Reporting
	to be	required	Type
	fulfilled		





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

25Change in the composition of an immediate-release solid oral dosage form including:

25a.1 replacement of a single excipient with a comparable excipient at a similar concentration	1 - 5	1 - 10	Vmin
25a.2	None	1 - 10	Vmaj
25b.1 quantitative changes in excipients	1 - 4	1 - 10	Vmin
25b.1 quantitative changes in excipients	None	1 - 4, 7 - 10	Vmaj

Conditions to be fulfilled

- 1.No change in functional characteristics of the pharmaceutical form.
- 2.Only minor adjustments (see Appendix 2) are made to the quantitative composition of the FPP; any minor adjustment to the formulation to maintain the total weight is made using an excipient which currently makes up a major part of the FPP formulation.
- 3. Stability studies have been started under conditions according to <PBSL> <quote respective Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (with indication of batch numbers)> and relevant stability parameters have been assessed in at least two pilot- or production-scale batches,





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

satisfactory stability data covering at least 3 months are at the disposal of the MAH, and the stability profile is similar to that of the currently accepted product.

- 4. The dissolution profile of the proposed product determined on a minimum of two pilot-scale batches is similar to the dissolution profile of the biobatch.
- 5. The change is not the result of stability issues and/or does not result in potential safety concerns, i.e. differentiation between strengths.

- clinical or comparative bioavailability **1.**Supporting or justification for not submitting a new bioequivalence study according to the current <PBSL> guidelines on bioequivalence
- **2.**(P.1) Description and composition of the FPP.
- **3.**(P.2) Discussion on the components of the proposed product (e.g., choice of excipients, compatibility of API and excipients), comparative multipoint in vitro dissolution profiles obtained on at least two batches of pilot- or production-scale of the proposed product and the biobatch (depending on the solubility and permeability of the drug, dissolution in the routine release medium or in multiple media covering the physiological pH range).
- 4.(P.3) Batch formula, description of manufacturing process and process controls, controls of critical steps and intermediates,






Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

process validation protocol and/or evaluation.

- **5.**(P.4) Control of excipients, if new excipients are proposed.
- **6.**(P.4.5) If applicable, either a CEP for any new component of animal origin susceptible to TSE risk or, where applicable, documented evidence that the specific source of the TSE risk material has been previously assessed by an PBSL in the ICH region or associated countries and shown to comply with the scope of the current guidelines in the countries of the ICH region or associated countries. The following information should be included for each such material: name of manufacturer, species and tissues from which the material is derived, country of origin of the source animals and its use.
- 7.(P.5) Copies of FPP release and shelf-life specifications and certificates of analysis for a minimum of two pilot- or production-scale batches. If applicable, data to demonstrate that the new excipient does not interfere with the analytical procedures for the FPP.
- **8.**(P.8.1) Results of stability testing generated on at least two pilotor production- scale batches with a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing.
- **9.**(P.8.2) Updated post-acceptance stability protocol and stability commitment to place the first production-scale batch of each strength of the proposed product into the long-term stability programme (bracketing and matrixing for multiple strengths and packaging components could be applied, if scientifically justified).




10.(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of the executed production documents for one batch, and confirmation that there are no changes to the production documents other than those highlighted.

5.2.4. Change or addition of imprints, embossing or other markings, including replacement or addition of inks used for product markings and change in scoring configuration

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
26Change or			
addition of			
imprints, embossing or other markings,			
including replacement or			
addition of inks used for product			
markings and change in scoring			
configuration involving:			





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar

26a changes in imprints, embossing 1 - 3 or other markings	1 - 2, 5 - 6	IN
26b deletion of a 2 – 5 score line	1, 5 - 6	IN
26c.1addition of a 2 - 4 score line	1, 3, 5- 6	Vmin
26c.2 addition of a None score line	1, 3-6	Vmaj


Conditions to be fulfilled

- 1.Any ink complies with section 3.2.P.4 of the <PBSL> Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product
- 2.The change does not affect the stability or performance characteristics (e.g. release rate) of the FPP.
- 3. Changes to the FPP specifications are those necessitated only by the change to the appearance or to the scoring.
- 4.Addition or deletion of a score line from a generic product is consistent with a similar change in the comparator product or was requested by <PBSL>.
- 5. The scoring is not intended to divide the FPP into equal doses.

Documentation required

1.Sample of the FPP.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

May Effective date: 17 May 2024 Approved by: Registrar


Issue date: 15 May 2024

- **2.**(P.1.) Qualitative composition of the ink, if purchased as a mixture.
- **3.**(P.2) Demonstration of the uniformity of the dosage units of the tablet portions, where the scoring is intended to divide the FPP into equal doses.
- **4.**(P.2) Demonstration of the similarity of the release rate of the tablet portions for gastro-resistant, modified or prolonged release products.
- **5.**(P.5) Copies of revised FPP release and shelf-life specifications.
- **6.**(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of the executed production documentation for one batch and confirmation that there are no changes to the production documents other than those highlighted.

5.2.5. Changes in dimensions without change in qualitative or quantitative composition and mean mass of

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
27Changes in			
dimensions without	:		
change in	1		
qualitative or	•		
quantitative			
composition and			





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

mean mass of:

27a tablets, capsules, suppositories and 1-22 - 6 ΙN pessaries other than those stated in change no. 27b

27bgastro-resistant, modified or prolonged-release

scored 1 - 2 1 – 6 Vmin **FPPs** and

tablets


Conditions to be fulfilled

- 1. Specifications for the FPP are updated only with respect to dimensions of the FPP.
- 2. Multipoint in vitro dissolution profiles of the current and proposed versions of the product (determined in the routine release medium, on at least one batch of pilot- or production-scale), are comparable.

Documentation required

gastro-resistant, modified or prolonged release FPPs, justification for not submitting a new bioequivalence study according to the current <PBSL> guidelines on bioequivalence. For scored tablets where the scoring is intended to divide the FPP into equal doses, demonstration of the uniformity of the





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: Registrar

tablet portions.

- 2. Sample of the FPP.
- **3.**(P.2) Discussion on the differences in manufacturing process(es) between the currently accepted and proposed products and the potential impact on product performance.
- **4.**(P.2) Comparative multipoint in vitro dissolution profiles in the routine release medium, on at least one batch of pilot- or production-scale of the current and proposed products.
- **5.**(P.5) Copies of revised FPP release and shelf-life specifications.
- **6.**(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of executed production documentation for one batch and confirmation that there are no changes to the production documents other than those highlighted.


3.2.P.3 Manufacture

5.2.6. Addition or replacement of a manufacturing site for part or all of the manufacturing process for an FPP involving:

Description of Change	Conditions	5	Documentation	Reporting
	to	be	required	Туре
	fulfilled			
20444:1:00				

28Addition or





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024Effective date: 17 May 2024

Approved by: Registrar

replacement of a manufacturing site for part or all of the manufacturing process for an FPP involving:

28a secondary packaging of all types of FPPs	2 - 3	1	IN
28b primary packaging site of:			
28b.1 solid FPPs (e.g., tablets, capsules), semi-solid FPPs (e.g., ointments, creams) and solution liquid FPPs	2 - 4	1, 8	IN
28b.2 other liquid FPPs (Suspensions, emulsions)	2 - 5	1, 5, 8	IN
28call other manufacturing operations except batch control and/or release testing	1 - 3, 5	1 - 9	Vmin
Conditions to be fulfi	lled		





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:
2024		Registrar

1.No change in the batch formula, description of manufacturing process and process controls, equipment class and process controls, controls of critical steps and intermediates, or FPP specifications.

- 2. Satisfactory inspection in the last three years either by <PBSL> or a Reference Institution (RI).
- 3. Site appropriately authorized by an PBSL (to manufacture the pharmaceutical form and the product concerned).
- 4. The change does not concern a sterile FPP.
- 5. Validation protocol is available or validation of the manufacturing process at the new site has been successfully carried out on at least three production-scale batches in accordance with the current protocol.

- **1.**Evidence that the proposed site has been appropriately authorized in the last three years, for the pharmaceutical form and the product concerned:
 - •a copy of the current manufacturing authorization, a GMP certificate or equivalent document issued by the PBSL;
 - •a GMP statement or equivalent issued by <PBSL> or a Reference Institution (RI);
 - •date of the last satisfactory inspection concerning the packaging facilities by WHO or a Reference Institution (RI) in the last three years.
- 2. Date and scope (with indication as to whether scope was e.g., product-specific or related to a specific pharmaceutical form) of the last






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

satisfactory inspection.

- **3.**(P.2) Where applicable, for semisolid and liquid formulations in which the API is present in non-dissolved form, appropriate validation data including microscopic imaging of particle size distribution and morphology.
- **4.**(P.2) For solid dosage forms, data on comparative dissolution tests in the routine release medium, with demonstration of similarity of dissolution profiles with those of the biobatch, performed on one production-scale batch each from current and proposed manufacturing sites and comparison with the biobatch results, with commitment to generate dissolution profiles on two more production-scale batches.
- **5.**(P.3.5) Process validation reports or validation protocol (scheme) for three batches of the proposed batch size, which includes comparative dissolution against the biobatch results with f2 calculation as necessary.
- **6.**(P.5.1) Copies of release and shelf-life specifications.
- **7.**(P.5.4) Batch analysis data on one production-scale batch from the proposed site and comparative data on the last three batches from the previous site.
- 8. (P.8.2) Updated post-acceptance stability protocol and stability commitment to place the first production-scale batch of the FPP produced at the new site into the long-term stability programme (bracketing and matrixing for multiple strengths and packaging components could be applied, if scientifically justified).
- 9. (R.1) Executed production documents for one batch of the FPP manufactured at the new site.




5.2.7. Replacement or addition of a site involving batch control testing

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
29Replacement or addition of a site involving batch control testing			
29a	1 - 2	1 - 3	AN

Conditions to be fulfilled

- 1.Site is appropriately authorized by the PBSL and satisfactorily inspected either by <PBSL> or a Reference Institution (RI).
- 2.Transfer of methods from the current testing site to the proposed testing site has been successfully completed.

- **1.**clear identification of the currently accepted and proposed quality control sites on the letter accompanying the application.
- **2.**Documented evidence that the site is appropriately authorized by the PBSL and satisfactorily inspected either by <PBSL> or a



Reference Institution (RI).

3.(P.5.3) Documented evidence of successful transfer of analytical procedures from the current to the proposed site


5.2.8. Change in the batch size of the FPP

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
30Change in the batch size of the			
FPP involving:			
30a up to and including a factor of 10 compared to the bio – batch	1 - 7	2, 5 -6	IN
30b Downscaling	1 – 5	2, 6	AN
30c other situations	1 - 7	1 - 7	Vmin

Conditions to be fulfilled

- 1. The change does not affect the reproducibility and/or consistency of the product
- 2. The change pertains only to immediate-release oral pharmaceutical





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


forms and to non-sterile liquid forms.

- 3. Changes to the manufacturing method and/or to the in-process controls are only those necessitated by the change in batch size, e.g. use of different-sized equipment.
- 4.A validation protocol is available or validation of the manufacture of three production-scale batches has been successfully undertaken in accordance with the current validation protocol.
- 5.The change is not necessitated by unexpected events arising during manufacture or because of stability concerns.
- 6. The change does not require supporting in vivo data.
- 7. The biobatch size was at least 100 000 units in the case of solid oral dosage forms.

Documentation required

1.(P.2) For solid dosage forms: dissolution profile data, in the routine release medium, on a minimum of one representative production-scale batch and comparison of the data with the biobatch results and one production-scale batch of the previous batch size. Data on the next two full production-scale batches should be available on request and should be reported if they do not meet dissolution profile similarity (f2) requirements. For semi-solid dosage forms (e.g. lotions, gels, creams and ointments), containing the API in the dissolved or non-dissolved form, comparative in vitro data on membrane diffusion (membrane release testing) should be submitted or be available on request.





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


Issue date: 15 May Effective date: 17 May 2024 Approved by:

2024

Effective date: 17 May 2024

Registrar

- **2.**(P.3.5) Process validation reports for three batches of the proposed batch size or validation protocol (scheme).
- **3.**(P.5.1) Copies of release and shelf-life specifications.
- **4.**(P.5.4) Batch analysis data (in a comparative tabular format) on a minimum of one production-scale batch manufactured to both the currently accepted and the proposed batch sizes. Batch data on the next two full production-scale batches should be available on request and should be reported immediately by the MAH of the product, if outside specifications (with proposed remedial action).
- **5.**(P.8.2) Updated post-acceptance stability protocol (approved by authorized personnel) and stability commitment to place the first production-scale batch of each strength at the proposed scale into the long-term stability programme (bracketing and matrixing for multiple strengths and packaging components could be applied, if scientifically justified).
- **6.**(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as relevant pages of the executed production documentation for one batch (if manufactured as required by documentation 4) (above) and confirmation that there are no changes to the production documents other than those highlighted.
- **7.**Supporting clinical or comparative bioavailability data or justification for not submitting a new bioequivalence study according to the current <PBSL> guidelines on bioequivalence.




5.2.9. Change in the manufacturing process of the FPP

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
31			
31a Change in the manufacturing process of the FPP	1 - 9	1 - 4, 6 - 7	AN
31b Change in the manufacturing process of the FPP	1 - 3, 5 - 9	1 - 7	Vmin

Conditions to be fulfilled

- 1. The change does not require supporting in vivo data.
- 2.No change in qualitative and quantitative impurity profile or in physicochemical properties; dissolution profiles are similar to those of the biobatch.
- 3.The manufacturing processes for the currently accepted and proposed products use the same principles (e.g. a change from wet to dry granulation, from direct compression to wet or dry granulation or vice versa would be considered a change in manufacturing principle), the same processing intermediates and there are no changes to any manufacturing solvent used in the process.
- 4.The same classes of equipment, operating procedures, in-process controls (with no widening or deleting of limits) are used for the currently accepted and proposed products; no change in critical process





Registrar

Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Tesue date: 15 May	Effective date: 17 May 2024	Annroyed by:

parameters.

2024

- 5. No change in the specifications of the intermediates or the FPP.
- 6.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 7. The change does not involve packaging or labelling where the primary packaging provides a metering and/or delivery function.
- 8.The change does not concern a gastro-resistant, modified or prolonged-release FPP.
- 9. The change does not affect the sterilization parameters of a sterile FPP.

- **1.**Supporting clinical or comparative bioavailability data or justification for not submitting a new bioequivalence study according to the current <PBSL> guidelines on bioequivalence.
- **2.**(P.2) Discussion on the development of the manufacturing process; where applicable:
 - •comparative in vitro testing, e.g., multipoint dissolution profiles in the routine release medium for solid dosage units (one production batch and comparative data on one batch from the previous process and the bio-batch results; data on the next two production batches should be available on request or reported if outside specification);
 - •comparative in vitro membrane diffusion (membrane release






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

testing) for non-sterile semisolid dosage forms containing the API in the dissolved or non- dissolved form (one production batch and comparative data on one batch from the previous process and the bio-batch results; data on the next two production batches should be submitted or be available on request);

- •microscopic imaging of particles to check for visible changes in morphology and comparative size distribution data for liquid products in which the API is present in non-dissolved form.
- **3.**(P.3) Batch formula, description of manufacturing process and process controls, controls of critical steps and intermediates, process validation protocol and/or evaluation.
- **4.**(P.5) Specification(s) and certificate of analysis for one production-scale batch manufactured according to the currently accepted process and for a batch manufactured according to the proposed process.
- **5.**(P.8.1) Results of stability testing generated on at least two pilot batches (for uncomplicated products, one pilot batch; the other one can be smaller) with a minimum of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing.
- **6.**(P.8.2) Updated post-acceptance stability protocol and stability commitment to place the first production-scale batch of the proposed product into the long-term stability programme.
- **7.**(R.1) Copies of relevant sections of blank master production documents with changes highlighted as well as executed




production documentation for one batch and confirmation that there are no changes to the currently accepted production documents other than those highlighted.

5.2.10. Change to in-process tests or limits applied during the manufacture of the FPP or intermediate

Description of Change		Documentation required	Reporting Type
32 Change to in- process tests or limits applied during the manufacture of the FPP or intermediate involving:			
32a tightening of in- process limits a	1 - 2, 5	1.	AN
32b deletion of a test	2 - 3	1, 6	AN
32c addition of new tests and limits	2 - 3	1 - 6	AN
32d revision or replacement of a test	2 - 3	1 - 6	IN






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:
2024		Registrar

Conditions to be fulfilled

- 1. The change is within the range of acceptance limits.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3. Any new test does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 4. The deleted test has been demonstrated to be redundant with respect to the remaining analytical procedures (e.g., colour) and does not affect the critical quality attributes of the product (e.g., blend uniformity, weight variation).
- 5.No change in the analytical procedure

- **1.**(P.5.1) Copy of the proposed in-process specifications dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- **2.**(P.5.2) Copies or summaries of analytical procedures, if new analytical procedures are used.
- **3.**(P.5.3) Copies or summaries of validation reports, if new analytical procedures are used.
- **4.**(P.5.3) Where an in-house analytical procedure is used and a pharmacopeial standard is claimed, results of an equivalence study between the in-house and pharmacopeial methods.




- **5.**(P.5.4) Description of the batches, certificates of analysis for at least one batch (minimum pilot-scale) and comparative summary of results, in tabular format, for one batch using current and proposed methods, if new analytical procedures are implemented.
- **6.**(P.5.6) Justification for the addition or deletion of the tests and limits.

3.2. P.4 Control of excipients

5.2.11. Change in source of an excipient from a TSE risk to a material of vegetable or synthetic origin

Description of Change	Conditions to be fulfilled	Docume required		porting pe
33 Change in source of an excipient from a TSE risk to a material of vegetable or synthetic origin				
33a	1	1	AN	
Conditions to be fulfi	lled			
1.No change in the	e excipient	and FPP	release and	shelf-life



specifications.


Documentation required

1.Declaration from the manufacturer of the excipient that it is entirely of vegetable or synthetic origin.

5.2.12. Change in the specifications or analytical procedures for an excipient

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
34 Change in the specifications or analytical procedures for an excipient involving			
34a deletion of a non- significant in-house parameter	2	1-3	AN
34b addition of a new test parameter or analytical Procedure	2-3,	1 - 2	AN






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May 2024	Effective date: 17 May 2024	Approved by: Registrar
2024		Registrar

34c tightening of specification Limits	1-2 4	1-2	AN
34d change or replacement of an analytical procedure	2-3	1-2	Vmin

Conditions to be fulfilled

- 1. The change is within the range of currently accepted limits.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3.Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 4. No change in the analytical procedure.

- **1.** Justification for the change.
- **2.**(P.5) Comparative table of currently accepted and proposed specifications, justification of the proposed specifications and details of procedure and summary of validation of any new analytical procedure (if applicable).
- **3.** Justification to demonstrate that the parameter is not critical



5.2.13. Change in specifications of an excipient to comply with an officially recognized pharmacopoeia

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
35 Change in specifications of an excipient to comply with an officially recognized pharmacopoeia	1	1	AN

Conditions to be fulfilled

1.No change to the specifications other than those required to comply with the pharmacopoeia (e.g. no change in particle size distribution).

Documentation required


1.Comparative table of currently accepted and proposed specifications for the excipient.

3.2. P.5 Control of FPP

5.2.14. Change in the standard claimed for the FPP from an inhouse to an officially recognized pharmacopeial standard

Description of Change	Conditions	Documentation	Reporting
	to be	required	Туре
		•	, '





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01


Issue date: 15 May 2024 Approved by: 2024 Registrar

fulfilled **36a Change in the** 1-3 1-5 ΑN standard claimed for the FPP from an in-house to officially recognized pharmacopeial standard 36b Update to the specifications to comply with an officially recognized ΑN

comply with an officially recognized pharmacopeial None 1,3,5 monograph as a result of an update to this monograph to which the FPP is Controlled

Conditions to be fulfilled

- 1.The change is made exclusively to comply with the officially recognized pharmacopoeia.
- 2.No change to the specifications that results in a potential impact on the performance of the FPP (e.g., dissolution test).
- 3.No deletion of or relaxation of any of the tests, analytical procedures or acceptance criteria of the specifications. Any deletion or relaxation of the tests should meet the conditions of 37a or 37d and should follow the corresponding reporting types.



Documentation required

- **1.**(P.5.1) Copy of the proposed FPP specifications dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- **2.**(P.5.3) Where an in-house analytical procedure is used and a pharmacopeial standard is claimed, results of an equivalence study between the in-house and pharmacopeial methods.
- **3.**(P.5.4) Description of the batches, certificates of analysis for at least one batch (minimum pilot-scale) and comparative summary of results, in tabular format, for one batch using current and proposed procedures, if new analytical procedures are implemented.
- **4.**(P.5.6) Justification for the proposed FPP specifications.
- **5.**(P.5.3) Demonstration of the suitability of the monograph to control the FPP.

5.2.15. Change in the specifications of the FPP involving test parameters and acceptance criteria

Description of Change	Conditions be fulfilled	to Documentation required	Reporting Type
37 Change in the specifications of the FPP involving test parameters and			



2024

Title: Guideline on Variation



Registrar


Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:

acceptance criteria:			
37adeletion of a test parameter	5	1-6	AN
37baddition of a test parameter	2-4,7	1 - 6	AN
37c tightening of an acceptance criterion	1-2	1, 6	AN
37d relaxation of an acceptance criterion	2, 4, 6-7	1, 5-6	IN
37e replacement of a test parameter	2-4, 6-7	1-6	IN

Conditions to be fulfilled

- 1. The change is within the range of currently accepted limits.
- 2.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 3.Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 4. No additional impurity found over the ICH identification threshold.
- 5.The deleted test has been demonstrated to be redundant with respect to the remaining tests.
- 6. The change to the specifications does not affect the stability and the performance of the product.






Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

7. The change does not concern sterility testing.


- **1.**(P.5.1) Copy of the proposed FPP specifications dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- 2.(P.5.2) Copies or summaries of analytical procedures, if new analytical procedures are used.
- **3.**(P.5.3) Copies or summaries of validation reports, if new analytical procedures are used.
- 4.(P.5.3) Where an in-house analytical procedure is used and a pharmacopoeial standard is claimed, results of an equivalence study between the in-house and pharmacopoeial methods.
- 5. (P.5.4) Description of the batches, certificates of analysis for at least one batch (minimum pilot-scale) comparative summary of results, in tabular format, for one batch using currently accepted and proposed procedures, if analytical new procedures are implemented.
- (P.5.6) Justification for the proposed FPP specifications. 6.



5.2.16. Change in the analytical procedures for the FPP

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
38 Change in the analytical procedures for the FPP involving:			
38a deletion of an analytical procedure	5	1, 6	AN
38b addition of an analytical Procedure	3-4, 6-7	1-5	AN
38c.1 modification or replacement of an analytical procedure	1-4, 6-7	1-5	AN
38c.2	2-4, 6-7	1-5	Vmin
38d updating the analytical procedure with an officially recognized pharmacopeial monograph as a result of an update to that Monograph	None	1–5	AN
38e change from an in-house analytical	2, 7	1-3, 5	IN





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

procedure to an analytical procedure in officially an recognized Pharmacopeial monograph or from the analytical procedure in one officially recognized pharmacopeial monograph to an analytical procedure in another officially Recognized pharmacopeial Monograph

Conditions to be fulfilled

- 1.The method of analysis is based on the same analytical technique or principle (e.g. changes to the analytical procedure are within allowable adjustments to column length and other parameters, but do not include variations beyond the acceptable ranges or a different type of column and method), and no new impurities are detected.
- 2.Comparative studies demonstrate that the proposed analytical procedure is at least equivalent to the currently accepted analytical procedure.
- 3.Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.






Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:
2024		Registrar

- 4. The change does not concern sterility testing.
- 5.The deleted analytical procedure is an alternative method and is equivalent to a currently accepted analytical procedure.
- 6.The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or because of stability concerns.
- 7.No new impurities have been detected.

- **1.**(P.5.1) A copy of the proposed FPP specifications dated and signed by authorized personnel and a comparative table of currently accepted and proposed specifications.
- **2.**(P.5.2) Copies or summaries of analytical procedures, if new analytical procedures are used.
- **3.**(P.5.3) Copies or summaries of validation reports, including verification data for assay or purity methods, if new analytical procedures are used.
- **4.**(P.5.3) Where an in-house analytical procedure is used and a pharmacopoeial standard is claimed, results of an equivalence study between the in-house and pharmacopoeial methods.
- **5.**(P.5.4) Description of the batches, certificates of analysis for at least one batch (minimum pilot-scale) and comparative summary of results, in tabular format, for one batch using currently accepted and proposed analytical procedures.
- **6.** Justification for the deletion of the analytical procedure, with



supporting data.

3.2.P.7 Container-closure system

5.2.17. Replacement or addition of a primary packaging type


Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
39 Replacement or addition of a primary packaging type			
39a Replacement or addition of a primary packaging type	1	1-2, 4-6.	Vmin
39b Replacement or addition of a primary packaging type	None	1-6	Vmaj

Conditions to be fulfilled

1. The change does not concern a sterile FPP.

- **1.**Samples of the product as packaged in the new container-closure system.
- **2.**(P.2) Data on the suitability of the container-closure system (e.g. extractable/ leachable testing, permeation testing, light





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar


transmission) demonstrating equivalent or superior protection compared to the current packaging system. For changes to functional packaging, data to demonstrate the functioning of the new packaging.

- **3.**(P.3.5) For sterile FPPs, process validation and/or evaluation studies.
- **4.**(P.7) Information on the proposed primary packaging type (e.g. description, materials of construction of primary packaging components, specifications, and results of transportation studies, if appropriate).
- **5.**(P.8.1) Stability summary and conclusions, results for a minimum of two batches of pilot- or production-scale, of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing and where applicable, results of photostability studies.
- **6.**(P.8.2) Updated post-acceptance stability protocol and stability commitment to place the first production-scale batch of the proposed product into the long-term stability programme, unless data were provided in documentation 5.

5.2.18. Change in the package size

Description of Change	Conditions	5	Documentation	Reporting
	to	be	required	Type
	fulfilled			





Registrar

Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Tssue date: 15 May	Effective date: 17 May 2024	Approved by:

40Change in the package size

involving:

2024


_			
40a change in the number of units (e.g., tablets, ampoules, etc.) in a package	1-2	1-2	Vmaj
40b.1 change in the fill weight or fill volume of non-parenteral multidose products	1-3	1-2	IN
40b.2 change in the fill weight or fill volume of non-parenteral multidose products	1-2	1-2	Vmin

Conditions to be fulfilled

- 1. The change is consistent with the posology and treatment duration accepted in the SmPC.
- 2. No change in the primary packaging material.
- 3. No increase in the headspace or surface/volume ratio.

Documentation required

1. Justification for the new pack-size, indicating that the new size is consistent with the dosage regimen and duration of use as



accepted in the SmPC.

2.(P.8.2) A written commitment that stability studies will be conducted in accordance with the <PBSL> guidelines for products where stability parameters could be affected.

5.2.19. Change in the shape or dimensions of the container or closure

Description of Change		Condition to	Documentation required	Reporting Type	
			fulfilled		
41 Change	in	the			

shape or dimensions of the container or closure


for:

41a non-sterile FPPs	1 – 2	1 - 3.	AN	
41b sterile FPPs	1 - 2	1 - 4	Vmin	

Conditions to be fulfilled

- 1.No change in the qualitative or quantitative composition of the container and/or closure.
- 2. The change does not concern a fundamental part of the packaging material, which could affect the delivery, use, safety or stability of the





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

FPP.

2024

Documentation required

- **1.**Samples of the product packaged in the new container-closure system.
- **2.**(P.7) Information on the proposed container-closure system (e.g., description, materials of construction, and specifications).
- **3.**(P.8.1) In the case of changes to the thickness of a packaging component or for sterile FPPs: stability summary and conclusions, results for a minimum of two batches of pilot- or production-scale, of 3 months of accelerated intermediate, as appropriate) and 3 months of long-term testing and, where applicable, results of photostability studies. In the case of a change in the headspace or a change in the surface/volume ratio for non-sterile FPPs, a commitment for the above studies.
- **4.**(P.3.5) Evidence of revalidation studies in the case of terminally sterilized products. The batch numbers of the batches used in the revalidation studies should be indicated, where applicable.

5.2.20. Change in qualitative and/or quantitative composition of the immediate packaging material

Des	scription of Change	Condition	S	Documentation	Reporting
		to	be	required	Type
		fulfilled			





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

42Change in qualitative and/or quantitative composition of the immediate packaging material for:


42a solid FPPs	1 - 3	1 - 3.	IN	
42b semisolid liquid FPPs	and 1 – 3	1 - 3	Vmin	

Conditions to be fulfilled

- 1. The change does not concern a sterile FPP.
- 2.No change in the packaging type and material (an example of an allowable change is blister to blister).
- 3. The relevant properties of the proposed packaging are at least equivalent to those of the currently accepted material

Documentation required

- **1.**(P.2) Data demonstrating the suitability of the proposed packaging material (e.g. extractable/leachable testing, light transmission, permeation testing for oxygen, carbon dioxide, and moisture).
- **2.**(P.7) Information on the proposed packaging material (e.g., description, materials of construction, and specifications).
- **3.**(P.8.1) Stability summary and conclusions, results of (or a




commitment to study in the case of demonstrated equivalent or more protective packaging) a minimum of two batches of pilot- or production-scale, of 3 months of accelerated (and intermediate, as appropriate) and 3 months of long-term testing and, where applicable, results of photostability studies.

5.2.21. Change in the specifications of the immediate packaging

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
43 Change in the specifications of the immediate packaging involving:			
43a tightening of specification limits	1 - 2	1	AN
43b addition of a test parameter	2 - 3	1 - 2	AN
43c deletion of a non- critical parameter	2	1, 3	AN
Conditions to be fulfi	lled		

onditions to be fulfilled

- 1. The change is within the range of currently accepted limits.
- 2. The change is not necessitated by failure to meet specifications resulting from unexpected events arising during manufacture, or



because of stability concerns.

3. Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.


Documentation required

- **1.**(P.7) Comparative table of currently accepted and proposed specifications, justification of the proposed specifications.
- **2.**(P.7) Description of the analytical procedure and summary of validation of the new analytical procedure.
- **3.**Documentation to demonstrate that the parameter is not critical.

5.2.22. Change to an analytical procedure on the immediate packaging

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
44 Change to an analytical procedure on the immediate packaging involving:			
44a minor change to an analytical procedure	1-3	1	AN






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: Registrar

Conditions to be fulfilled

- 1.The method of analysis is based on the same analytical technique or principle (e.g. changes to the analytical procedure are within allowable adjustments to column length and other parameters, but do not include variations beyond the acceptable ranges or a different type of column and method).
- 2.Appropriate (re)validation studies have been performed in accordance with the relevant guidelines.
- 3.comparative studies indicate the new analytical procedure to be at least equivalent to the former procedure.
- 4. Any new analytical procedure does not concern a novel, non-standard technique or a standard technique used in a novel way.
- 5. The deleted analytical procedure is an alternative method and is equivalent to a currently accepted method.


Documentation required



- **1.**(P.7) Description of the method and comparative validation results demonstrating that the currently accepted and proposed methods are at least equivalent.
- **2.**Documentation to demonstrate the equivalence of the deleted method and a currently accepted method

5.2.23. Change in any part of the (primary) packaging material not in contact with the FPP formulation (e.g., colour of flip-off caps, colour code rings on ampoules, or change of needle shield)

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
45 Change in any part of the (primary) packaging material not in contact with the FPP formulation (e.g., colour of flipoff caps, colour code rings on ampoules, or change of needle shield).			
45a	1	1 - 2	:N



Conditions to be fulfilled


1. The change does not concern a fundamental part of the packaging material, which affects the delivery, use, safety or stability of the FPP.

Documentation required

- **1.**(P.7) Information on the proposed packaging material (e.g. description, materials of construction, and specifications).
- **2.**Sample of the FPP.

5.2.24. Change to an administration or measuring device that is not an integral part of the primary packaging (excluding spacer devices for metered dose inhalers

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
46 Change to an administration or measuring device that is not an integral part of the primary packaging (excluding spacer devices for metered			



dose inhale involving:	ers)			
46a addition replacement	or _{1, 2}	1 - 2	IN	
46b Deletion	3	3	IN	

Conditions to be fulfilled

- 1.The proposed measuring device is designed to accurately deliver the required dose for the product concerned in line with the posology, and results of such studies are available.
- 2. The proposed device is compatible with the FPP.
- 3. The FPP can be accurately delivered in the absence of the device.

Documentation required


- **1.**(P.2) Data to demonstrate accuracy, precision and compatibility of the device.
- **2.**Sample of the device.
- **3.** Justification for the deletion of the device

3.2.P.8 Stability

5.2.25. Change in the shelf-life of the FPP (as packaged for sale)

Description of Change	Conditions	Documentation	Reporting
	to	pe	





Type

Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

required

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

fulfilled

2024

47 Change the in shelf-life of the FPP (as packaged for sale) involving:


47a reduction	3	1-3	IN
47b extension	1-2	1-3	Vmin

Conditions to be fulfilled

- 1. No change to the primary packaging type in direct contact with the FPP and to the recommended conditions of storage.
- 2. Stability data were generated in accordance with the currently accepted stability protocol.
- 3. The change is not necessitated by unexpected events arising during manufacture or because of stability concerns.

Documentation required

- **1.**(P.5.1) Copy of the currently accepted shelf-life specifications.
- **2.**(P 8.1) Proposed shelf-life, summary of long-term stability testing according to currently accepted protocol and test results for a minimum of two pilot- or production-scale batches for a period sufficient to support the proposed shelf-life.
- **3.**(P.8.2) Updated post-acceptance stability protocol and stability



commitment and justification of change.

5.2.26. Change in the in-use period of the FPP (after first opening or after reconstitution or dilution)


Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
48 Change in the inuse period of the FPP (after first opening or after reconstitution or dilution):			
48a reduction	1	1	IN
48b extension	None	1-2	Vmin

Conditions to be fulfilled

1. The change is not necessitated by unexpected events arising during manufacture or because of stability concerns..

Documentation required

1.(P 8) Proposed in-use period, test results and justification of



change.

2.(P 5.1) Copy of currently accepted end of shelf-life FPP specifications and, where applicable, specifications after dilution or reconstitution.

5.2.27. Change in the labelled storage conditions of the FPP (as packaged for sale), the product during the in- use period or the product after reconstitution or dilution

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
49 Change in the labelled storage conditions of the FPP (as packaged for sale), the product during the in- use period or the product after reconstitution or dilution	1	1-2	Vmin

Conditions to be fulfilled

1. The change is not necessitated by failure to meet specifications






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

resulting from unexpected events arising during manufacture, or because of stability concerns.

Documentation required

- **1.**(P.8.1) If applicable, stability and/or compatibility test results to support the change to the storage conditions.
- **2.**(P.8.2) Updated post-acceptance stability protocol and stability commitment and justification of change.




6. Safety and Efficacy Changes

6.1. Change(s) in the Summary of Product Characteristics, Labelling or Patient information leaflet of a generic/hybrid medicinal products following assessment of the same change for the reference product.

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
50 Change(s) in the Summary of Product Characteristics, Labelling or Patient information leaflet of a generic/hybrid medicinal products following assessment of the same change for the reference product			
50a Implementation of change(s) for which no new additional data is required to be submitted by the MAH		1, 2	Vmin
50b Implementation of change(s) which require to be further substantiated by new additional data to be		1,2,3	Vmaj





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

submitted by the MAH (e.g., comparability)

- 1. Attached to the cover letter of the variation application: Reasoning for the applied change (generics following innovator's change in product information).
- 2. Revised product information in track changes and as clean version.
- 3. Data substantiating the applied changes.
- 6.2. Change(s) in the Summary of Product Characteristics, Labelling or Patient Information Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the <PBSL>.

51 Change(s) in the Summary of Product Characteristics, Labelling or Patient information leaflet of human medicinal products intended to implement the	Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
Characteristics, Labelling or Patient information leaflet of human medicinal products intended to	51 Change(s) in the			
Labelling or Patient information leaflet of human medicinal products intended to	Summary of Product			
information leaflet of human medicinal products intended to	Characteristics,			
human medicinal products intended to	Labelling or Patient			
products intended to	information leaflet of			
•	human medicinal			
implement the	products intended to			
	implement the			





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the <PBSL>

51a Implementation of 1 wording agreed by the PBSL.

1, 2

ΙN

51b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH


2, 3

Vmaj

Conditions

1. The variation implements the wording requested by the PBSL and it does not require the submission of additional information and/or further assessment.


- 1. Attached to the cover letter of the variation application: reference to the agreement/assessment of the PBSL.
- 2. Revised product information.
- 3. Data substantiating the applied changes.



6.3. Change(s) in the Summary of Product Characteristics, Labelling or Patient Information Leaflet due to new quality, non-clinical, clinical or pharmacovigilance data.

Description of Change	Conditions Documentatio to be required fulfilled	n Reporting Type
52 Change(s) in	1,2,3	Vmaj
the Summary of		
Product		
Characteristics,		
Labelling or		
Patient		
Information		
Leaflet due to new		
quality, non-		
clinical, clinical or		
pharmacovigilance		
data.		

- 1. Attached to the cover letter of the variation application: reference to the agreement/assessment of the <PBSL>.
- 2. Revised product information.
- 3. Data substantiating the applied changes.




Note: this variation does not apply when the new data has been submitted under variation 51(Section 7.2). In such cases, the change(s) in the SmPC, labelling and/or patient information leaflet is covered by the scope of variation 51.

6.4. Change in the legal status of a medicinal product.

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
53 Change in the legal status of a medicinal product			
53a All legal status changes		1, 2	Vmaj

- 1.Attached to the cover letter of the variation application: proof of authorization of the legal status change (e.g., reference to change in category of distribution, product classification e.g., change in orphan designation).
- 2. Revised product information





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024Effective date: 17 May 2024

Approved by: Registrar

6.5. Change(s) to therapeutic indication(s)

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
54 Change(s) to therapeutic			
indication(s)			
54a Addition of a new therapeutic indication or modification of an authorized one			Vmaj
54b Deletion of a therapeutic indication			Vmin

Note: where the change takes place in the context a variation for a generic — when the same change has been done for the reference product, variations 50 (Section 7,1) apply.

6.6. Deletion of pharmaceutical form and a strength

Description of Change	 Documentation required	Reporting Type
55 Deletion of:		





Rev No: 00	Doc No: PBSL/GL/026	Version no. 01
Issue date: 15 May	Effective date: 17 May 2024	Approved by:
2024		Registrar

55a pharmaceutical form	1, 2	Vmin	
55b strength	1, 2	Vmin	

Documentation

1. Declaration that the remaining product presentation(s) are adequate for the dosing instructions and treatment duration as mentioned in the summary of product characteristics.

2. Revised product information


Note: in cases where a given pharmaceutical form or strength has received a marketing authorisation which is separate to the marketing authorisation for other pharmaceutical forms or strengths, the deletion of the former will not be a variation but the withdrawal of the marketing authorisation.

In cases where a given pharmaceutical strength has separate SmPC for each marketing authorisation this variation is not applicable

6.7. Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
56 Introduction of, or			
change(s) to, the			
obligations and			





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024Effective date: 17 May 2024

Approved by: Registrar

conditions of a marketing authorisation, including the risk management plan

56a Implementation of wording agreed by the <PBSL>

1

1, 2

ΙN

56b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the <PBSL> is required (*)

Vmaj


Conditions

1. The variation implements the action requested by the authority and it does not require the submission of additional information and/or further assessment.

Documentation

1. Attached to the cover letter of the variation application: A reference to





Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

the relevant decision of the <PBSL>.

2. Update of the relevant section of the dossier.

Note: this variation covers the situation where the only change introduced concerns the conditions and/or obligations of the marketing authorisation, including the risk management plan and the conditions and/or obligations of marketing authorisations under exceptional circumstances and conditional marketing authorisation.

(*) the introduction of a risk management plan requested by the <PBSL> always requires significant assessment.


6.8. Other variations not specifically covered elsewhere in this guideline which involve the submission of studies to the <PBSL>.

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
57 Other variations not specifically covered elsewhere in this guideline which involve the submission of studies to the <pbsl> (*)</pbsl>			

Vmaj

Note: in cases where the assessment by the <PBSL> of the data submitted leads to a change of the Summary of Product Characteristics,






Rev No: 00 Doc No: PBSL/GL/026 Version no. 01

Issue date: 15 May 2024 Approved by: 2024 Registrar

Labelling or Patient information leaflet, the relevant amendment to the Summary of Product Characteristics, Labelling or Patient information leaflet is covered by the variation.

Documentation

(*) This variation does not apply to variations that can be considered as Vmin by default under any other section of this guideline.




7. Changes to the labelling or the patient information leaflet which are not connected with the summary of product characteristics.

Description of Change	Conditions to be fulfilled	Documentation required	Reporting Type
58 Changes to the labelling or the patient information leaflet which are not connected with the summary of product characteristics.			
58a Administrative information concerning the local agent		1	IN
58b Other changes		1	Vmin
Documentation			
1. Revised product infor	mation.		

Definitions

The definitions provided below apply to the terms used in this guidance. They may have different meanings in other contexts and documents.



Active pharmaceutical ingredient (API)

A substance used in the FPP, intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings.

Active pharmaceutical ingredient (API) starting material

A raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in-house.

MAH


A person or entity whose product has been authorized by a national medicines regulatory authority to be on the market.

Biobatch

The batch used to establish bioequivalence or similarity to the comparator product as determined in bioequivalence or biowaiver studies, respectively.

Final intermediate

The last reaction intermediate in the synthetic pathway that undergoes synthetic transformation to the API or the crude API. Purification is not considered to be a synthetic transformation.



Finished pharmaceutical product (FPP)

A finished dosage form of a pharmaceutical product which has undergone all stages of manufacture including packaging in its final container and labelling.

In-process control

Check performed during manufacture to monitor or to adjust the process in order to ensure that the final product conforms to its specifications.

Manufacturer

A company that carries out operations such as production, packaging, repackaging, labelling and re-labelling of pharmaceuticals.


Officially recognized pharmacopoeia (or compendium)

Those pharmacopoeias recognized by the <PBSL> (i.e. <title of respective Pharmacopoeia/s>).

Pilot-scale batch

A batch of an API or FPP manufactured by a procedure fully representative of and simulating that to be applied to a full production-scale batch. For example, for solid oral dosage forms, a pilot scale is generally, at a minimum, one-tenth that of a full production scale or 100 000 tablets or capsules, whichever is the larger, unless otherwise adequately justified.

Production batch



A batch of an API or FPP manufactured at production scale by using production equipment in a production facility as specified in the application.

Reference Institution (RI)/ Reference Regulatory Authority

An authority or institution which assessment and its outcome serve regulatory reliance. per WHO for As (https://www.who.int/news/item/29-04-2021-who-publishes-newguidance-to-promote-strong-efficient-and-sustainable-regulatorysystems) this encompasses different levels of reliance. In this document this term relates to a list of authorities/institutions determined by the PBSL including the transitional WHO listed authorities referred as B+C to group (https://www.who.int/publications/m/item/list-of-transitional-wlas) and WHO Prequalification Programme.

Supplier

A person or entity providing pharmaceutical materials on request. Suppliers may be agents, brokers, distributors, manufacturers or traders. Where possible, suppliers should be authorized by a competent authority.





Rev No: 00 Version no. 01 Doc No: PBSL/GL/026

Issue date: 15 May Effective date: 17 May 2024 Approved by: Registrar

2024

References

WHO TRS 981 - Annex 3: WHO guidelines on variations to a pregualified product

EUROPEAN COMMISSION; Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures.

WHO - Quality Assurance of Medicines Terminology Database - List of Terms and related quideline, October2023. https://cdn.who.int/media/docs/default-source/medicines/norms-andstandards/guidelines/mga-terminology-sept-2020.pdf?sfvrsn=48461cfc_10 (Accessed May 2024)

This guideline is structured in line with guidelines from the European Medicine Agency (EMA). This guideline template was modified and included in the harmonized Guideline on Guidelines V1, Update December 2022, developed by the Joint Technical Working Group for Guidelines in Marketing Authorization (TWG-MAG).

Appendix 1: Examples of changes that make a new application or extension application necessary

Description of change	Condition	ons	Documentation	Reporting
	to	be	required	type
	fulfilled			
1. Change of the API to a	None		1	New
different API				application/
2. Inclusion of an additional API				extension
in a multicomponent product				application
3. Removal of one API from a				
multicomponent product				
4. Change in the dose and/or				
strength of one or more APIs				
5. Change from an immediate				
release product to an				
extended or delayed-release				
dosage form or vice versa				
6. Change from a liquid to a				
powder for reconstitution or vice				
versa				
7. Changes in the route of				
administration				
Conditions to be fulfilled None				

Conditions to be fulfilled None

Documentation required

Documentation in fulfilment of the requirements outlined in the <PBSL> guidelines for registration of Drugs

Appendix 2: Changes to excipients

Excipient	Percentage excipient (w/w) out of total target dosage form core weight
Filler	± 5.0
Disintegrant	
•starch	± 3.0
•other	± 1.0
Binder	± 0.5

Lubricant	
•Ca or Mg Stearate	± 0.25
•other	± 1.0
•Glidanttalc	± 1.0
•other	± 0.1

[■]These percentages are based on the assumption that the active pharmaceutical ingredient (API) in the finished pharmaceutical product (FPP) is formulated to 100.0% of label/potency declaration. The total additive effect of all changes to excipients should be not more than 5.0% relative to the target dosage form weight (e.g. in a product consisting of API, lactose, microcrystalline cellulose and magnesium stearate, the lactose increases by 2.5% and microcrystalline cellulose decreases by 2.5%).

 \blacksquare If an excipient serves multiple functions (e.g. microcrystalline cellulose as a filler and as a disintegrant), then the most conservative recommended range should be applied (e.g. \pm 1.0% for microcrystalline cellulose should be applied in this example). If a wider range is proposed, scientific justification and supporting data should be provided to demonstrate that the wider range will not affect the other function of the excipient.